REVIEW article

Front. Cell. Infect. Microbiol., 24 July 2018

Sec. Microbiome in Health and Disease

Volume 8 - 2018 | https://doi.org/10.3389/fcimb.2018.00243

The Clinical Importance of Campylobacter concisus and Other Human Hosted Campylobacter Species

  • School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia

Article metrics

View details

108

Citations

25,8k

Views

5,6k

Downloads

Abstract

Historically, Campylobacteriosis has been considered to be zoonotic; the Campylobacter species that cause human acute intestinal disease such as Campylobacter jejuni and Campylobacter coli originate from animals. Over the past decade, studies on human hosted Campylobacter species strongly suggest that Campylobacter concisus plays a role in the development of inflammatory bowel disease (IBD). C. concisus primarily colonizes the human oral cavity and some strains can be translocated to the intestinal tract. Genome analysis of C. concisus strains isolated from saliva samples has identified a bacterial marker that is associated with active Crohn's disease (one major form of IBD). In addition to C. concisus, humans are also colonized by a number of other Campylobacter species, most of which are in the oral cavity. Here we review the most recent advancements on C. concisus and other human hosted Campylobacter species including their clinical relevance, transmission, virulence factors, disease associated genes, interactions with the human immune system and pathogenic mechanisms.

Introduction

Campylobacter, along with Arcobacter and Sulfurospirillum, are the three genera that belong to the family, Campylobacteraceae. Campylobacter species are Gram-negative, curved or spiral shaped, and most of them are motile with a single polar flagellum present at one or both ends of the bacteria, allowing them to have a corkscrew-like motion during movement (Lastovica et al., 2014). Campylobacter species have low G + C content in their genome, and the median G + C content for most of the Campylobacter species ranges from 28 to 40% (Pruitt et al., 2007). There are few Campylobacter species which have G + C content of more than 40% in their genomes, including Campylobacter curvus, Campylobacter rectus, Campylobacter showae and Campylobacter gracilis (Pruitt et al., 2007). A majority of the Campylobacter species are microaerophiles, while some require anaerobic conditions for their growth (Debruyne et al., 2008).

Most Campylobacter species live as normal flora in the gastrointestinal tract of various animals (Lastovica et al., 2014). Some of these animal hosted Campylobacter species, such as Campylobacter jejuni and Campylobacter coli, can cause acute bacterial gastroenteritis in humans through consumption of contaminated food or water (Galanis, 2007). In addition to gastroenteritis, C. jejuni also causes Guillain-Barré syndrome, due to molecular mimicry between its sialylated lipooligosaccharides and the human nerve gangliosides (Takahashi et al., 2005).

As C. jejuni and C. coli are the main Campylobacter pathogens which cause human acute intestinal disease and they originate from animal sources, Campylobacteriosis has historically been considered to be zoonotic. Several Campylobacter species utilize humans as their natural host and accumulated evidence supports their role in chronic inflammatory diseases of the human intestinal tract. Here we review recent advancements on human hosted Campylobacter species, their clinical relevance, transmission, virulence factors, disease associated genes, interactions with human immune system and pathogenic mechanisms. Most of the studies on the human hosted Campylobacter species in the past decade were on Campylobacter concisus, this bacterium is therefore the focus of this review. In addition, other human hosted Campylobacter species were also reviewed.

The natural hosts of Campylobacter species and human diseases associated with Campylobacter species

The natural host of a bacterium refers to the host that the bacterium normally lives and reproduces (Haydon et al., 2002; Control and Prevention, 2006). Bacterial species are usually not harmful to their hosts, although there are exceptions. For example, Helicobacter pylori is a human hosted bacterial species, causing gastritis and gastric ulcers and being a risk factor for gastric cancer (Roesler et al., 2014).

To date, 40 Campylobacter species and subspecies have been isolated from a wide variety of animal or human sources (Figure 1). Many Campylobacter species are naturally hosted by domesticated animals raised as food such as chicken, cattle and pigs (Lastovica et al., 2014). They survive as commensal bacteria in their hosts, and some species, such as C. jejuni and C. coli, can cause human diseases. The main human disease caused by animal hosted pathogenic Campylobacter species is acute gastroenteritis and clinical disorders can also arise if bacterial species colonizing sterile sites of the body (Table 1). A number of Campylobacter species are also able to cause diseases in animals. For example, Campylobacter fetus is known to cause abortion in bovine and ovine, and Campylobacter hepaticus is the causative agent of spotty liver disease in chicken (Campero et al., 2005; Van et al., 2016).

Figure 1

Figure 1

Phylogenetic tree based on the 16S rRNA gene of Campylobcter species. The tree was generated using the maximum likelihood method implemented in MEGA7. Bootstrap values were generated from 1000 replicates. Bootstrap values of more than 70 were indicated. Escherichia coli MG1655 was included as an outgroup. Human hosted Campylobacter species are in blue. Campylobacter geochelonis was not included because its 16S rRNA sequence was not available.

Table 1

Campylobacter species Isolation sources Clinical relevance of human diseases References
Campylobacter coli Gastroenteritis: feces
Bacteraemia: blood
Septic abortion: blood; maternal placenta; amniotic fluid
Acute cholecystitis: gallbladder
Retroperitoneal abscess
Meningitis: CSF
Gastroenteritis*
Abortion*
Bacteraemia*
Skirrow, 1977; Kist et al., 1984; Blaser et al., 1986; Møller Nielsen et al., 1997; Lastovica and Roux, 2000; Galanis, 2007; Liu Y. H. et al., 2017;
Campylobacter fetus subsp. fetus Bacteraemia: blood
Gastroenteritis: feces
Meningitis: feces; blood; CSF
Chorioamnionitis: blood
Cellulitis lesion: subcutaneous aspirate
Cellulitis and bacteraemia: blood; feces
Abortion: vagina; feces; blood; gastric aspirate; skin; liver; spleen; lung; spinal fluid
Postsurgical abscess: groin abscess
Post abortion infection: amniotic fluid
Hemiparesis and aphasia: blood
Cystic fibrosis: feces
Surgical fever: blood
Fever, chills, endocarditis: blood
Immune deficiency disease: blood
Sepsis, encephalitis, fever, myalgia: blood and CSF
Cellulitis and diarrhea: ankle abscess
Post-neurosurgery for metastatic esophagocardial carcinoma: brain abscess
Chronic alcoholism: brain abscess
Prematurity: brain abscess
Heroin and barbiturate abuse: pulmonary abscess
Alcoholism: gluteal abscess; blood
Post-hemilaminectomy for disc herniation: epidural mass in pyogenic vertebral osteomyelitis
Hyperthyroidism: thyroid gland abscess
Bacteraemia*
Abortion*
Meningitis*
Abscess*
Gastroenteritis
Blaser et al., 1980a,b; Edmonds et al., 1985; Francioli et al., 1985; La Scolea, 1985; Klein et al., 1986; Simor et al., 1986; Morrison et al., 1990; Sauerwein et al., 1993; Kwon et al., 1994; Neuzil et al., 1994; Steinkraus and Wright, 1994; Morooka et al., 1996; Ichiyama et al., 1998; Lastovica and Roux, 2000; Viejo et al., 2001; Krause et al., 2002; Fujihara et al., 2006; De Vries et al., 2008; Liu Y. H. et al., 2017
Health status unknown: Blood and synovial fluid
Campylobacter fetus subsp. testudinum Leukemia: blood
Liver cancer (bloody diarrhea, pulmonary edema): pleural fluid
Asthma: hematoma
Lymphoma, hypertension, and heart disease (fever, chills, rigor, cough, and diarrhea): blood
Diarrhea: bile
Diabetes (cellulitis of leg): blood
Leukemia* Tu et al., 2004; Patrick et al., 2013
Campylobacter fetus subsp. venerealis Bacteraemia: blood
Infective aneurysm: blood Vaginosis
Garcia et al., 1995; Tu et al., 2001; Hagiya et al., 2015; Liu Y. H. et al., 2017
Health status unknown: blood
Campylobacter helveticus Health status unknown: feces Lawson et al., 1997
Campylobacter hyointestinalis (subsp. hyointestinalis and lawsonii) Proctitis: rectum
Gastroenteritis: feces
Gastroenteritis* Fennell et al., 1986; Edmonds et al., 1987; Lastovica and Roux, 2000; Gorkiewicz et al., 2002
Campylobacter insulaenigrae Gastroenteritis: blood
Bacteraemia: blood
Gastroenteritis
Bacteraemia*
Chua et al., 2007
Campylobacter jejuni (subsp. jejuni and doylei) Bacteraemia: blood; feces
Gastroenteritis: feces
Sepsis: blood, feces, placenta
Meningitis: CSF
Appendicitis: appendix
Myocarditis: feces
Reactive arthritis: feces
Guillain-Barré syndrome: feces
Fisher syndromes: feces; gastric biopsy; CSF
Recurrent colitis: blood; feces
Acute cholecystitis: gallbladder
Urinary tract infection: urine
Chronic renal failure: peritoneal prodialysis fluid
Ovarian cyst: peritoneal cyst fluid
Thoracic wall abscess: thoracic wall
Meningitis and hypogammaglobulinemia: CSF
Gastroenteritis*
Bacteraemia*
Guillain-Barré syndrome*
Meningitis*
Appendicitis
Myocarditis
Reactive arthritis
Skirrow, 1977; Thomas et al., 1980; Gilbert et al., 1981; Megraud et al., 1982; Chan et al., 1983; Blaser et al., 1986; Dhawan et al., 1986; Goossens et al., 1986; Klein et al., 1986; Kohler et al., 1988; Korman et al., 1997; Meyer et al., 1997; Møller Nielsen et al., 1997; Manfredi et al., 1999; Lastovica and Roux, 2000; Wolfs et al., 2001; Hannu et al., 2002, 2004; Cunningham and Lee, 2003; Takahashi et al., 2005; Lastovica, 2006; Galanis, 2007; Pena and Fishbein, 2007; Mortensen et al., 2009; Liu Y. H. et al., 2017
Campylobacter lanienae Healthy: feces Logan et al., 2000
Campylobacter lari (subsp. concheus and lari) Urinary tract infection: urine
Bacteraemia: blood
Gastroenteritis: feces
Bacteraemia* Bézian et al., 1990; Morris et al., 1998; Lastovica and Roux, 2000; Martinot et al., 2001; Krause et al., 2002; Werno et al., 2002
Campylobacter mucosalis Gastroenteritis: feces Figura et al., 1993
Campylobacter peloridis Health status unknown: feces Debruyne et al., 2009
Campylobacter sputorum (biovar faecalis, paraureolyticus, sputorum, and bubulus) Gastroenteritis: feces
Axillary abscess
Leg abscess
Pus from pressure sore
Gastroenteritis
Abscess*
Roop Ii et al., 1985; Steele et al., 1985; Lindblom et al., 1995; Tee et al., 1998; De Vries et al., 2008
Health status unknown: oral cavity; feces
Campylobacter troglodytis Gastroenteritis: feces Platts-Mills et al., 2014
Campylobacter upsaliensis Abortion: blood and fetoplacental material
Bacteraemia: blood
Gastroenteritis: feces
Breast abscess
Gastroenteritis
Bacteraemia*
Lastovica et al., 1989; Gurgan and Diker, 1994; Jimenez et al., 1999; Lastovica and Roux, 2000; Lastovica and Le Roux, 2001; De Vries et al., 2008

Clinical relevance of animal hosted Campylobacter species.

CSF, cerebrospinal fluid.

*

Campylobacter species that have established associations with human diseases or have been isolated from a sterile site. Species which have not yet been isolated from humans were not included.

Campylobacter species hosted by humans include C. concisus, C. curvus, C. gracilis, Campylobacter hominis, C. rectus, and C. showae; to date these six Campylobacter species have only been isolated from humans (Hariharan et al., 1994; Zhang, 2015). Campylobacter ureolyticus was isolated from human samples in most cases, with only one study isolating C. ureolyticus from the endometria of healthy horses (Hariharan et al., 1994). Therefore, in this review, C. ureolyticus is considered as a human hosted Campylobacter species. In contrast to animal hosted Campylobacter pathogens, the human hosted Campylobacter pathogens are more often involved in chronic inflammatory conditions of the gastrointestinal tract (Table 2).

Table 2

Campylobacter species Isolation sites in human Clinical relevance of human diseases References
Campylobacter concisus Healthy: saliva; subgingival site; intestinal biopsy; feces Inflammatory bowel disease*
Diarrheal diseases
Barrett's esophagus*
Periodontal disease
Tanner et al., 1981; Lindblom et al., 1995; Lastovica and Roux, 2000; Macuch and Tanner, 2000; Lastovica, 2006; Macfarlane et al., 2007; De Vries et al., 2008; Zhang et al., 2010; Kalischuk and Inglis, 2011; Mukhopadhya et al., 2011; Nielsen et al., 2011, 2013; Blackett et al., 2013; Mahendran et al., 2013; Zhang, 2015; Kirk et al., 2016
IBD: saliva; intestinal biopsy
Diarrhea: feces
Barrett's esophagus: esophageal aspirate; distal esophageal biopsy
Brain abscess: secondary to chronic frontal osteomyelitis
Periodontal disease: subgingival site
Campylobacter curvus Healthy: subgingival site Gastroenteritis
Abscess
Koga et al., 1999; Lastovica and Roux, 2000; Macuch and Tanner, 2000; Abbott et al., 2005; Petersen et al., 2007; De Vries et al., 2008; Mendz et al., 2014; Horio et al., 2017
Periodontal disease: subgingival and periodontitis site
Thoracic empyema: pleural effusion
Premature birth: vaginal swabs
Alveolar abscess
Metastatic ovarian cancer: liver abscess
Liver abscess: blood
Lung cancer: bronchial abscess
Guillain-Barré syndrome: feces
Fisher's syndrome: feces
Gastroenteritis: feces
Campylobacter gracilis Healthy: subgingival site Periodontal disease* Tanner et al., 1981; Johnson et al., 1985; Yu and Chen, 1997; Macuch and Tanner, 2000; De Vries et al., 2008; Shinha, 2015
Bacteraemia: blood
Brain abscess (post-partum)
Tubo-ovarian abscess
Periodontal disease: subgingival and periodontitis site
Visceral or head and neck infection
Campylobacter hominis Healthy: feces Septicaemia Lawson et al., 1998, 2001; Linscott et al., 2005; Zhang et al., 2009
Septicaemia: blood
CD: intestinal biopsy
Campylobacter rectus Healthy: subgingival site Periodontal diseases*
IBD
Von Troil-Lindén et al., 1995; Lastovica and Roux, 2000; Macuch and Tanner, 2000; Han et al., 2005; Macfarlane et al., 2007; De Vries et al., 2008; Mahlen and Clarridge, 2009; Zhang et al., 2009; Man et al., 2010b; López et al., 2011; Mukhopadhya et al., 2011; Lee et al., 2012; Leo and Bolger, 2014; Noël et al., 2018
Periodontal disease: subgingival and periodontitis site
Barrett's esophagus: distal esophageal mucosal biopsy
Fatal thoracic empyema: pleural liquid
Septic cavernous sinus thrombosis: blood
Gastroesophageal adenocarcinoma: palate abscess
Breast abscess
Vertebral abscess
Gastroenteritis: feces
Campylobacter showae Healthy: subgingival site; gingival crevices IBD Etoh et al., 1993; Macuch and Tanner, 2000; De Vries et al., 2008; Zhang et al., 2009; Man et al., 2010b; Suzuki et al., 2013
Periodontal disease: subgingival and periodontitis site
CD: intestinal biopsy
Intraorbital abscess
Bacteraemia: blood
Campylobacter ureolyticus Healthy:
Male: urine
Female: genital tract
IBD
Gastroenteritis
Genital tract diseae
Duerden et al., 1982, 1987, 1989; Johnson et al., 1985; Bennett et al., 1990, 1991; Petersen et al., 2007; Zhang et al., 2009; Bullman et al., 2011; Mukhopadhya et al., 2011; O'doherty et al., 2014
CD: intestinal biopsy
Gastroenteritis: feces
Periodontal disease: deep periodontal pockets
Superficial soft tissue or bone infections
Male:
Non-gonococcal, non-chlamydial urethritis
Non-gonococcal urethritis
Superficial necrotic or gangrenous lesions
Penile wound
Female:
Perineal, genital and peripheral ulcers
Genital tract: excess vaginal discharge; lower genital tract symptoms
Health status unavailable: Amniotic fluid; urine

Clinical relevance of human hosted Campylobacter species.

*

Campylobacter species that have established associations with human diseases or have been isolated from a sterile site.

C. concisus

C. concisus has a curved or spiral shape and a single polar flagellum, with the size being 0.5–1 by 4 μm (Tanner et al., 1981). Its colony appears as convex shaped, translucent and is ~1 mm in diameter (Tanner et al., 1981). In early literature, C. concisus was described as a microaerophile, due to the growth of this bacterium under microaerophilic atmosphere enriched with hydrogen (H2) (Lastovica, 2006). Later, Lee et al. demonstrated that C. concisus is not a microaerophile, as they found that none of the 57 C. concisus strains grew in the microaerophilic conditions generated using the Oxoid BR56A and CN25A gas-generation systems (Lee et al., 2014). These C. concisus strains were able to grow under anaerobic conditions, with tiny colonies observed after 3 days of culture under anaerobic conditions, showing that C. concisus is an anaerobic bacterium. The anaerobic condition used in the study was generated using AN25A gas-generation system which absorbs oxygen with simultaneous production of CO2.

C. concisus is a chemolithotrophic bacterium, capable of using H2 as a source of energy to markedly increases its growth (Lee et al., 2014). C. concisus is able to oxidize H2 under both anaerobic and microaerobic conditions, although greater growth was observed under anaerobic conditions in the presence of 2.5–10% H2 (Lee et al., 2014). C. concisus is catalase negative, contributing to its inability to grow under microaerobic conditions (Tanner et al., 1981).

Transmission of C. concisus

Currently, humans are the only known hosts of C. concisus with oral cavity being its natural colonization site (Zhang et al., 2010; Mahendran et al., 2013). C. concisus has been isolated from saliva samples of children as early as 3 years old, although the positive isolation rate was significantly lower than the other age groups (33 vs. 79–88%); and the highest C. concisus isolation rate was seen in the age group of 12–17 (Zhang et al., 2010) (Figure 2). When a PCR method was used for detection, the children from the 3 to 5 years old age bracket had a detection rate that was similar to other age groups (83 vs. 93–100%). These data show that although C. concisus colonize humans at the early stages of life, 3–5 year old children have lower bacterial loads of C. concisus in their saliva as compared to older children and the adults. Currently, no data are available regarding C. concisus colonization in children below 3 years old.

Figure 2

Figure 2

Detection and isolation rates of C. concisus from saliva samples in different age groups. The PCR detection rate of C. concisus from children of different age groups varied between 80 and 100%. However, the isolation rate of C. concisus from children at 3–5 years was only 33% (4/12), which was significantly lower than that in other age groups, indicating younger children were colonized with lower numbers of bacteria. Data are from Zhang et al. (2010).

Given that C. concisus colonizes the oral cavity, transmission would occur through saliva. The stability of C. concisus in saliva samples is related to sample storage. We were able to isolate C. concisus from saliva samples stored at 4°C for 3–6 days. However, we were unable to isolate C. concisus from the same saliva samples after storage at room temperature for 24 h. This suggests that in addition to direct contact, C. concisus contaminated food or drinks, particularly those stored in refrigerators, may also play a role in C. concisus transmission. Multiple strains of C. concisus have been isolated from saliva samples and enteric samples of given individuals, suggesting a possible dynamic colonization of new C. concicus strains in the human gastrointestinal tract (Ismail et al., 2012).

Association of C. concisus with human diseases

Gingivitis and periodontitis

Gingivitis is a common bacterial disease which affects 90% of the population (Coventry et al., 2000). The oral mucosa consists of stratified squamous epithelial cells (Lumerman et al., 1995). Periodontitis develops when gingivitis is not well-treated (Pihlstrom et al., 2005). As disease progresses, a loss of attachment between the gingivae and the teeth leads to the formation of a periodontal pocket, which then allows extensive colonization by anaerobic bacteria causing further inflammation of the mucosa (Highfield, 2009). In periodontitis patients, higher proportions of Gram-negative and anaerobic bacterial species are present in the oral cavity as compared to healthy controls (Newman and Socransky, 1977). C. concisus was initially isolated from the oral cavity of patients with gingivitis and periodontitis (Tanner et al., 1981). However, studies have not revealed a clear association between C. concisus and gingivitis and periodontitis, its role in human oral inflammatory diseases remains unclear.

Barrett's esophagus

The esophagus is a muscular conduit with stratified squamous epithelial layers; its mucosa is colonized by microbes dominated by members of the genus Streptococcus (Di Pilato et al., 2016). Disturbances of the microbiota composition, such as the abnormal enrichment of some Gram-negative bacteria including Campylobacter spp. has been reported to be associated with gastroesophageal reflux disease (GERD), and is suggested to contribute to the development toward Barrett's esophagus and oesophageal adenocarcinoma (Di Pilato et al., 2016).

By analyzing the microbiome composition in biopsy samples of the distal esophagus collected from normal individuals and patients with esophagitis or Barrett's esophagus, Yang et al. found that type I microbiome (Gram-positive aerobic microbiome) was mainly associated with normal esophagus (11/12, 91.7%), while type II microbiome (Gram-negative anaerobic microbiome) was more closely associated with abnormal esophagus including esophagitis and Barrett's esophagus (13/22, 59.1%) (Yang et al., 2009). Furthermore, Campylobacter species was found to be one of the genera with increased abundance in type II microbiome (Yang et al., 2009).

By using bacterial cultivation methods, Macfarlane et al. found that high levels of C. concisus and C. rectus were present in oesophageal aspirate and mucosal samples of patients with Barrett's esophagus, but not in control subjects (Macfarlane et al., 2007). Similar findings were reported by another study, in which the Campylobacter genus dominated by C. concisus colonized patients with GERD and Barrett's esophagus with increased bacterial counts, accompanied by a significant decrease in bacterial counts for all other genera (Blackett et al., 2013). This relationship was not observed in patients with oesophageal adenocarcinoma. It is possible that C. concisus contributes to the inflammation associated with GERD and Barrett's esophagus.

Gastroenteritis

Gastroenteritis is an inflammatory condition of the gastrointestinal tract which is characterized by diarrhea, abdominal pain, fever and vomiting (Galanis, 2007). It is usually self-limiting within 2–5 days (Galanis, 2007). Gastroenteritis can be caused by bacteria, viruses, parasites and fungi; the most common causes are rotavirus and bacterial species such as Escherichia coli, C. jejuni, and C. coli (Galanis, 2007).

A number of studies have reported the isolation of Campylobacter species other than C. jejuni and C. coli in diarrheal stool samples. Lindblom et al. found that in stool samples from diarrheal patients, Campylobacter upsaliensis, Campylobacter sputorum, and C. concisus were the most common species in addition to C. jejuni, of which C. concisus was only isolated from children (Lindblom et al., 1995). Similarly, Lastovica et al. reported that in addition to C. jejuni, C. concisus was the second most frequently isolated Campylobacter species from diarrheic stools of pediatric patients (Lastovica and Roux, 2000). Nielsen et al. also found that C. concisus was more frequently found in diarrheal stool samples of young children and elderly (Nielsen et al., 2013). The same group later reported a clinical study comparing clinical manifestations between adult patients infected with C. concisus and C. jejuni/C. coli, and they showed that although C. concisus infection seems to induce a milder course of acute gastroenteritis in comparison to that induced by C. jejuni/C. coli, it is associated with prolonged diarrhea (Nielsen et al., 2012). Recently, Serichantalergs et al. reported a significantly higher detection rate of C. concisus in traveller's diarrhea cases as compared to that in asymptomatic controls in Nepal (Serichantalergs et al., 2017). Another recent study by Tilmanne et al. showed that C. concisus had a similar prevalence in children with acute gastroenteritis as compared with the control group (Tilmanne et al., 2018). Unfortunately, most of the studies that reported the isolation of C. concisus from diarrheal stool samples did not have control fecal samples from healthy individuals, making it difficult to judge the role of this bacterium in gastroenteritis; and for those studies with control groups included, the results were controversial. Thus, whether C. concisus plays a role in gastroenteritis remains to be investigated.

Inflammatory bowel disease

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract with Crohn's disease (CD) and ulcerative colitis (UC) being two of its major forms (De Souza and Fiocchi, 2016). The two forms of IBD mainly differ in pathology. CD is characterized by having discontinuous “skip lesions” of transmural inflammation and the abnormalities can be found throughout the gastrointestinal tract (Walsh et al., 2011). In contrast to CD, the inflammation involvement for UC is usually confined to the mucosa and submucosa without skip lesions and mostly occurs in the large intestine (Walsh et al., 2011).

The etiology of IBD is not fully understood. Accumulated evidence has suggested that the mucosal immune system in genetically predisposed individuals has mounted responses to intestinal commensal bacterial species, which is believed to contribute to the pathogenesis of IBD (Knights et al., 2013). Intestinal commensal bacterial species have co-evolved with the intestinal mucosal immune system thus the immune responses to intestinal commensal bacterial species would need an external trigger. Microbes that have the ability to cause a prolonged primary intestinal barrier defect or alter the mucosal immune system are more likely to trigger IBD.

C. concisus is commonly present in the oral cavities of almost all individuals. However, patients with IBD have a significantly higher prevalence of C. concisus detected in their intestinal tissues as compared to healthy controls (Zhang et al., 2009, 2014; Man et al., 2010b; Mahendran et al., 2011; Mukhopadhya et al., 2011; Kirk et al., 2016). Comparison of the housekeeping genes and genomes of oral and enteric C. concisus strains suggests that enteric strains originate from oral C. concisus strains (Ismail et al., 2012; Chung et al., 2016).

C. concisus, C. hominis, C. showae, and C. ureolyticus have also been isolated from patients with CD. Additionally, C. homonis, C. showae, C. rectus, C. gracilis, and C. ureolyticus have been detected from fecal specimens of children with newly diagnosed CD (Zhang et al., 2009; Man et al., 2010b). However, no association has been found between the prevalence of these Campylobacter species in CD patients and healthy controls.

Genomospecies of C. concisus

C. concisus strains can be separated into two major genomospecies (GS), consistently defined by the analysis of core genomes and housekeeping genes (Istivan, 2005; Miller et al., 2012; Mahendran et al., 2015; Chung et al., 2016; Nielsen et al., 2016). C. concisus 23S rRNA gene has polymorphisms, which was also used to define the genomospecies by comparison of the entire 23S rRNA gene sequence or PCR amplification of 23S rRNA gene fragments (Engberg et al., 2005; Kalischuk and Inglis, 2011; On et al., 2013; Huq et al., 2017; Wang et al., 2017).

Quantitative PCR methods targeting the polymorphisms of the 23S rRNA gene revealed that there were more GS2 than GS1 C. concisus in samples collected from the upper and lower gastrointestinal tract of both patients with IBD and healthy controls, suggesting that GS2 C. concisus is better adapted to the human gastrointestinal tract (Wang et al., 2017). A meta-analysis of the composition of the isolated GS1 and GS2 C. concisus strains showed similar findings except that in healthy individuals, a significantly lower number of GS2 C. concisus strains than GS1 C. concisus were isolated from fecal samples. This suggests a potential difference in the C. concisus strains or the enteric environment between patients with gastrointestinal diseases and healthy controls (Wang et al., 2017).

The two GS of C. concisus do not differ in morphology but have GS-specific genes and may have different pathogenic potentials. By examining C. concisus strains isolated from diarrheal fecal samples, Engberg et al. found that bloody diarrhea was only present in individuals infected with GS2 C. concisus strains (Engberg et al., 2005). Furthermore, Kalischuk and Inglis demonstrated that GS2 C. concisus exhibited higher levels of epithelial invasion and translocation (Kalischuk and Inglis, 2011). Similarly, Ismail et al. reported that the oral C. concisus strains that were more invasive to intestinal epithelial cells were GS2 strains (Ismail et al., 2012).

Recently, comparative genomic analyses have identified two novel genomic islands CON_PiiA and CON_PiiB that carry proteins homologous to the type IV secretion system, LepB-like and CagA-like effectors (Chung et al., 2016). CON_PiiA and CON_PiiB were found in strains from both GS1 and GS2 (Chung et al., 2016). The effects of the proteins possessed by CON_PiiA and CON_PiiB on human cells require further examination.

Both GS1 and GS2 contain diverse C. concisus strains. The isolation sources of C. concisus strains do not seem to contribute to the phylogenetic relatedness. C. concisus strains isolated from saliva, intestinal biopsies and feces are found in both GS1 and GS2, as are the strains isolated from patients with enteric disease and healthy controls. A recent study examining the genomes of 104 C. concisus strains isolated from saliva, mucosal biopsies and fecal samples of patients with IBD, gastroenteritis and healthy individuals showed that sampling site rather than disease phenotype was associated with the particular GS (Kirk et al., 2018). In that study, authors reported that genes involved in cell membrane synthesis were common in oral strains, while those related to cell transport, metabolism, and secretory pathways were more often found in enteric isolates. These results indicate that GS alone is unable to differentiate virulent C. concisus strains from commensal strains.

A recent study reported the identification of an exoprotein named C. concisus secreted protein 1 (Csep1) (Liu et al., 2018). The csep1 gene was found to be localized in the bacterial chromosome and the pICON plasmid. The chromosomally encoded csep1 gene was only found in GS2 C. concisus strains, while the pICON plasmid encoded csep1 gene was found in both GS1 and GS2 strains. Some csep1 genes contained a six-nucleotide insertion at the position 654–659 bp (csep1-6bpi). Importantly, the csep1-6bpi gene in oral C. consisus strains was found to be associated with active CD. So far, the csep1-6bpi gene is the only molecular marker in C. concisus reported to have an association with IBD.

Pathogenic mechanisms of C. concisus

Motility, adhesion, and invasion

Campylobacter movement through the mucus layer is driven by its polar flagellum, which is crucial for approaching, attaching, and invading the intestinal epithelial cells (Young et al., 2007). In C. jejuni, the extracellular flagella filament is composed of multimers of flagellin proteins with a major flagellin protein FlaA and a minor flagellin protein FlaB. FlaA has been shown to be essential for invasion of INT 407 cells and optimal colonization in chicken gut (Wassenaar et al., 1991, 1993). The flagellum also serves as a type III secretion system for transportation of Campylobacter invasion antigens to the host cells (Buelow et al., 2011; Neal-Mckinney and Konkel, 2012; Samuelson et al., 2013).

Both C. concisus and C. jejuni are spiral shaped. Unlike C. jejuni. which can have either single or bi-polar flagella, C. concisus only has a single polar flagellum. Although the flagellum in C. concisus has not been comprehensively investigated, studies have shown that C. concisus flagellum might be a virulence factor that contributes to its pathogenicity. Man et al. have observed flagellum mediated attachment and invasion of C. concisus to Caco-2 cells (Figure 3) (Man et al., 2010a).

Figure 3

Figure 3

Potential pathogenetic mechanisms of virulent C. concisus strains. Once it reaches the intestine, C. concisus adheres and invades the epithelium with the help of its flagellin and spiral shape. This is followed by a number of host responses such as cytoskeletal rearrangement, inflammasome assembly, expression of toll-like receptors, and the release of proinflammatory cytokines. Expression of virulence factors such as the zonula occludens toxin also results in proinflammatory cytokine production, as well as apoptosis (colored in red). The resulting compromised intestinal epithelium allows the increased translocation of commensal bacteria and their products from the lumen to the lamina propria. Proinflammatory cytokines and chemokines released by intestinal epithelial cells recruit immune cells to the site of infection and contributes to inflammatory response development.

Several studies have examined the motility of C. concisus strains isolated from saliva, feces and intestinal biopsies of patients with IBD, gastroenteritis, and healthy individuals. The motility was shown to be strain dependent, and no statistically significant association was found between patients and healthy controls (Lavrencic et al., 2012; Ovesen et al., 2017). The authors also reported that the motility of C. concisus was lower than that of C. jejuni and C. fetus (Ovesen et al., 2017). Furthermore, comparative genomic analysis of C. concisus strains had identified proteins required for flagellin glycosylation pathway, which may affect bacterial flagellar filament assembly, autoagglutination, adhesion and invasion (Kaakoush et al., 2011).

Bacterial flagella are also involved in forming biofilm, a bacterial interaction that is important for its survival in the host (Reeser et al., 2007; Svensson et al., 2014). C. concisus was also shown to have the ability to form biofilms, and this ability did not differ between the strains examined (Lavrencic et al., 2012).

Damaging the intestinal epithelial barrier

The intestinal epithelium is constructed by simple columnar epithelial cells (Clevers, 2013). Increased intestinal permeability is known to be associated with a number of chronic human diseases including IBD, being considered as a risk factor for its development (Hollander et al., 1986; Wyatt et al., 1993; Irvine and Marshall, 2000; D'Incà et al., 2006; Meddings, 2008). A compromised intestinal epithelial barrier may lead to loss of tolerance to the commensal enteric microbiota. Using in vitro cell culture models, several studies have indicated that C. concisus is able to increase the intestinal permeability. The intestinal epithelial permeability in Caco-2 cells was increased following C. concisus infection, and C. concisus also induced movement of tight junction proteins zonula occludens-1 and occludin from cell membrane into cytosol (Figure 3) (Man et al., 2010a). These changes in tight junction protein arrangement significantly increased the barrier permeability (Man et al., 2010a). These effects were also observed in HT-29/B6 intestinal epithelial cells, in which the cell monolayers infected with both oral and fecal C. concisus strains revealed epithelial barrier dysfunction (Nielsen et al., 2011).

Induction of proinflammatory cytokines

Inflammatory cytokines are produced in enteric infections (Figure 3). C. concisus strains were able to stimulate the productions of interleukin (IL)-8 and tumor necrosis factor (TNF)-α in THP-1 macrophages, and the productions of IL-8 and cyclooxygenase (COX)-2 in HT-29 cells (Man et al., 2010a; Ismail et al., 2013). COX-2 is an enzyme responsible for producing prostaglandins and other inflammatory mediators (Williams et al., 1999). Some C. concisus strains, mostly those isolated from patients with IBD, have been shown to upregulate surface expression of lipopolysaccharides (LPS) receptors including Toll-like receptor (TLR) 4 and myeloid differentiation factor 2 in HT-29 cells (Ismail et al., 2013). Activation of neutrophil adherence molecule CD11b and oxidative burst response have been shown in neutrophils following C. concisus infection (Sørensen et al., 2013). Additionally, by using transcriptomics analysis, assembly of IFI16 inflammasome has been observed in both intestinal epithelial cells and macrophages following C. concisus infection (Kaakoush et al., 2015; Deshpande et al., 2016). The IFI16 inflammasome plays important role in the innate immune responses, acting as a nuclear pathogen sensor that promotes caspase-1 activation (Xiao, 2015). Production of mature proinflammatory cytokines, IL-1β, and 1L-18, is caspase-1 dependent (Xiao, 2015). A recent study has found that C. concisus was able to elevate the mRNA expression of p53, TNF-α, and IL-18 in Barrett's cell lines, however these effects have not been demonstrated at protein level (Namin et al., 2015).

Flagellin from various Gram-negative and Gram-positive bacteria are capable of triggering nuclear factor kappa light chain enhancer of activated B cells (NF-κB) signaling responses in intestinal epithelial cells, where it is recognized by TLR5 expressed on the surface of the host cells (Eaves-Pyles et al., 2001; Gewirtz et al., 2001). The conserved region on flagellin that is recognized by TLR5 has been studied in Salmonella typhimurium (Smith et al., 2003). Campylobacter flagellin shares limited sequence similarity with that of S. typhimurium, which explains why it is a poor stimulator of TLR5 (Watson and Galán, 2005). Studies have demonstrated that C. jejuni, C. coli, and C. concisus have limited potential to activate TLR5 (De Zoete et al., 2010; Ismail et al., 2013).

To date, only two virulence factors of C. concisus have been characterized, one of which is the zonula occludens toxin (Zot). Initially described in Vibrio cholerae, Zot is a known virulence factor that causes an increase in intestinal permeability. The zot genes in Campylobacter species are encoded by prophages and are divided into two clusters, which encode ZotCampyType_1 and ZotCampyType_2, respectively (Zhang et al., 2014; Liu et al., 2016). Although the two types of Zot toxins share common motifs, their overall sequence identities vary greatly, particularly at the C-terminal compartment (Liu et al., 2016). Mahendran et al. have detected a similar prevalence of the cluster 1 zot gene in the oral C. concisus strains isolated from patients with IBD and healthy controls (Mahendran et al., 2013). Later on, Mahendran and colleagues found that the ZotCampyType_1 caused prolonged damage on Caco-2 monolayers (Mahendran et al., 2016). The damaging effect is different from that of V. cholerae Zot which induces transient and reversible damage to the intestinal epithelium (Fasano et al., 1991). This prolonged damaging effect induced by C. concisus Zot is at least partially due to the induction of cell apoptosis and/or intestinal epithelial cell production of proinflammatory cytokines such as TNF-α and IL-8 (Mahendran et al., 2016). Furthermore, pre-exposure to Zot causes increased phagocytosis of E. coli K12 by THP-1 macrophages, suggesting a possible role for C. concisus in enhancing responses of macrophages to other enteric bacterial species (Mahendran et al., 2016). Additionally, transcriptomics analysis showed that C. concisus Zot was able to upregulate the expression of TLR3, proinflammatory cytokines IL-6, IL-8, and chemokine CXCL16 (Deshpande et al., 2016). The zot-containing prophages are also found in a number of other human and animal hosted Campylobacter species including C. ureolyticus, Campylobacter corcagiensis, C. gracilis, C. jejuni, Campylobacter hyointestinalis, and Campylobacter iguanorium, however their pathogenic effects on human cells have not been examined (Liu et al., 2016).

In additional to Zot, another C. concisus virulence factor characterized is the membrane protein phospholipase A. Istivan et al. have examined the activity of haemolytic phospholipase A2 (PLA2) from C. concisus strains isolated from children with gastroenteritis and found that PLA2 activity is detected in strains from both GS. Membrane extracts containing PLA2 exhibited cytolytic effects on CHO cells, supporting the idea that C. concisus may have potential to cause tissue destruction related to intestinal inflammation (Istivan et al., 2004).

To date, only one study has examined the effects of C. concisus in animal model (Aabenhus et al., 2008). Mice displayed a significant loss of body weight between day 2 and day 5 following C. concisus inoculation via gastric route. Signs of inflammation in the gut were not consistently found, but micro abscesses were found in liver of infected animals. Additionally, infiltration of lymphocytes was also observed in the jejunum and colon of infected mice. However, the details of the C. concisus strains used were not provided.

Responses to environmental factors

Environmental factors present in the gastrointestinal tract such as bile and pH have been found to affect the growth of C. concisus in vitro (Ma et al., 2015). Reduction in C. concisus growth was observed with lower pH. The gastric pH values in patients with CD and UC range between 1.5–4.1 and 1.55–4.4, respectively, which are significantly higher than those in healthy individuals (0.95–2.6) (Press et al., 1998). Under laboratory conditions, C. concisus strains were unable to grow following exposure to pH 2 for 30 min, while only 20% of the strains were able to survive following exposure to pH 3.5 for 30 min, and exposure to pH 5 for 120 min had minor effects on C. concisus growth (Ma et al., 2015). The sensitivity of C. concisus toward low pH suggests that the acidic environment may prevent C. concisus from colonizing the stomach and intestinal tract. The less acidic gastric environment observed in patients with IBD may provide a better condition for C. concisus colonization (Press et al., 1998). Recently, Ma et al. reported that the derivatives of the food additive, fumaric acid, were able to enhance the growth of C. concisus strains (Ma et al., 2018). It was found that C. concisus strains showed the greatest increase in growth when cultured in media containing 0.4% of neutralized fumaric acid, neutralized monosodium fumarate and sodium fumarate. These results imply that removal of fumaric acid and its salts from diet of patients with IBD may help to improve their condition.

Campylobacter species have different ability in bile resistance. Some oral C. concisus strains are able to grow in the presence of 2% bile, suggesting they are able to survive in the enteric environment. Enteric Campylobacter species such as C. jejuni and C. hominis are bile resistant. Fox et al. have demonstrated that although significant growth inhibition was observed when C. jejuni was cultured in the presence of 2.5% bile, C. jejuni was still able to proliferate in cultures containing 5% bile (Fox et al., 2007). Lawson et al. showed that C. hominis strains isolated from stool samples were able to tolerate 2% bile (Lawson et al., 2001).

Antimicrobial resistance of C. concisus

There has been an increase in antibiotic resistance in Campylobacter isolates from both humans and animals worldwide (Luangtongkum et al., 2009; Iovine, 2013). Among antimicrobial therapies for treatment of Campylobacter enteritis, fluoroquinolones, and macrolides are most commonly used, while tetracyclines are rarely used (Alfredson and Korolik, 2007). Intravenous aminoglycosides are sometimes used to treat serious bacteraemia and other Campylobacter induced systemic infections (Alfredson and Korolik, 2007). Campylobacter species resist antibiotics by several mechanisms such as modification or occupation of target sites thus preventing the binding of antibiotic compounds; efflux pump systems that reduce intracellular antibiotic concentrations; changes in bacterial membrane permeability that prevents entering of antibiotic compounds; and hydrolysis of antibiotic compounds (Alfredson and Korolik, 2007; Iovine, 2013). The resistance determinants in C. jejuni and C. coli and their mechanisms of action have been widely studied, however the resistance determinants in C. concisus have not been investigated in detail. It is thought that antibiotics resistance has not developed in C. concisus as it is susceptible to a variety of antibiotics, of which tetracycline, erythromycin, ciprofloxacin, and macrolides are most commonly reported (Johnson et al., 1986; Aabenhus et al., 2005; Vandenberg et al., 2006; Nielsen et al., 2013). Ciprofloxacin, along with other antibiotics, have been shown to be effective in treating certain phenotypes of CD (Sartor, 2004).

Antibiotics are used as primary or adjuvant treatment along with anti-inflammatory and immunosuppressive drugs for the treatment of IBD (Sartor, 2004). Antibiotics are used to selectively reduce tissue invasion, decrease luminal, and mucosal bacterial loads and their translocation (Sartor, 2004). Some patients with IBD are colonized with multiple C. concisus strains, and a significantly higher prevalence of multiple oral C. concisus strains in patients with active IBD than healthy controls has been reported (Mahendran et al., 2013). Furthermore, for IBD patients who are in remission, those without antibiotic treatment usually have a higher prevalence of multiple oral C. concisus strains than those who were receiving antibiotics, indicating antibiotics were able to alleviate but not eradicate C. concisus growth in the intestinal tract (Mahendran et al., 2013).

In addition to antibiotics, the antimicrobial potentials of immunomodulating and anti-inflammatory drugs used for IBD treatments have not been widely tested. Immunosuppressive drugs such as azathioprine (AZA) and mercaptopurine (MP) used in the treatment of IBD have been reported to exhibit inhibitory effect on the growth of C. concisus strains, with the effect of AZA being more potent than MP (Liu F. et al., 2017). In their use as immunosuppressive drugs, both AZA and MP are eventually metabolized to purine analogs that interfere with DNA synthesis in immune cells (Nielsen et al., 2001). However, bioinformatics analysis has not identified all the enzymes required for AZA and MP metabolism in the C. concisus genome, indicating the inhibitory action of AZA and MP on C. concisus growth is not through the conventional pathway. AZA and MP can also reduce the growth of Mycobacterium avium subsp. paratuberculosis, another bacterium that is associated with human CD (Sanderson et al., 1992; Collins et al., 2000; Sieswerda and Bannatyne, 2006; Greenstein et al., 2007; Shin and Collins, 2008).

5-aminosalicylic acid (5-ASA) is an anti-inflammatory drug that is also commonly used to induce and maintain remission in IBD (Hanauer, 2006; Nikfar et al., 2009). Its effect on C. concisus growth varies between strains as it inhibits the growth of some C. concisus strains, while it promotes the growth of other strains, features which appears to be independent of C. concisus GS (Schwartz et al., 1982). Although 5-ASA is often used in the treatment of IBD, in some cases 5-ASA medications are found to cause exacerbations of colitis (Schwartz et al., 1982). The enhancement of C. concisus growth induced by 5-ASA may have implications in the deteriorated clinical conditions observed in patients with IBD following 5-ASA medications.

While antimicrobials may be effective in limiting the growth of C. concisus in the intestinal tract, continuous transportation of C. concisus from the oral cavity along with saliva and food makes eradication of this bacterium a challenge. Thus, antimicrobials targeting C. concisus in the oral cavity, particularly virulent strains, should be developed.

C. rectus

C. rectus (formerly named as Wolinella recta) is a small, straight, rod shaped, single polar flagellated bacterium with the size being 0.5 by 2–4 μm (Tanner et al., 1981). The colonies of C. rectus appear as convex shaped and spread or corrode blood agar plates (Tanner et al., 1981). C. rectus was initially identified using anaerobic condition consisting of 80% N2, 10% CO2, and 10% H2, although the study indicated that some stains can grow in the presence of 5% oxygen (Tanner et al., 1981). A number of studies have used anaerobic conditions for the isolation of C. rectus from different clinical samples such as dental plaques, feces, and oesophageal mucosal biopsies (Rams et al., 1993; Gmur and Guggenheim, 1994; Von Troil-Lindén et al., 1995; Lastovica and Roux, 2000; Macuch and Tanner, 2000; Macfarlane et al., 2007). A study comparing different atmospheric conditions on the growth of C. rectus demonstrated that its growth could be observed at 30, 35, and 42°C under anaerobic conditions; in contrast it did not grow in a conventional microaerophilic atmosphere consisting 5% O2, 10% CO2, and 85% N2 (Mahlen and Clarridge, 2009). Given all these findings, C. rectus is an anaerobic bacterium instead of microaerophilic bacterium.

C. rectus was first isolated from individuals with periodontal diseases (Tanner et al., 1981). It has since been isolated from various locations of the oral cavity including periodontal sulcus, tongue, cheek mucosa, and saliva (Könönen et al., 2007; Cortelli et al., 2008). C. rectus is predominantly localized in the middle and deep periodontal pocket zones, and tends to form clumps in tooth-attached and epithelium associated plaque areas (Noiri et al., 1997). A number of studies have reported the association between C. rectus and periodontal diseases. Macuch and Tanner detected C. rectus from 90% (42/47) of the subgingival sites of initial and established perondontitis individuals, which was signficianlty higher than that from gingivitis subjects (20%, 3/14) and healthy controls (10%, 2/18) (Macuch and Tanner, 2000). Dibart et al. also showed that C. rectus had a signfiicantly higher prevalence in supragingival plaque obtained from periodontally diseased subjects as comapred with healthy individuals (7/24 vs. 0/27) (Dibart et al., 1998). Furthermore, von Troil-Lindenl et al. reported that C. rectus was more frequently detected in saliva samples of subjects with advanced periondontitis (100%, 10/10) as comapred with individuals with initial or no periondontitis (40%, 4/10) (Von Troil-Lindén et al., 1995). Additionally, several studies have examined the prevalence of C. rectus in periondontitis patients with different disease status, however healthy subjects were not included. Several virulence factors of C. rectus including LPS, GroEL-like protein, and surface-layer protein have been characterized.

C. rectus acts as a stimulator of inflammation in the gingival tissue. It has been shown to enhance the production of IL-6 and IL-8 in human gingival fibroblasts (Dongari-Bagtzoglou and Ebersole, 1996). IL-6 is a multifunctional cytokine, as it can be both proinflammatory and anti-inflammatory, and its secretion is thought to drive the tissue damaging process in diseases such as periodontal disease (Irwin and Myrillas, 1998). C. rectus LPS is able to stimulate both plasmin activity and plasminogen activator activity in human gingival fibroblasts (Ogura et al., 1995). Plasmin is an enzyme that is converted from plasminogen via plasminogen activator catalysis (Martel-Pelletier et al., 1991). Plasmin is present in blood which degrades many blood plasma proteins such as fibrin clots (Martel-Pelletier et al., 1991). Significantly enhanced activities of plasmin and plasminogen activator activities have been observed in gingival fluid in periodontal disease (Hidaka et al., 1981; Talonpoika et al., 1990). Furthermore, C. rectus LPS also induces higher levels of IL-6 and prostaglandin E2 productions in aged human gingival fibroblasts as compared with those in younger cells, which may explain the increased susceptibility of periodontal disease in aged individuals (Ogura et al., 1996; Takiguchi et al., 1996, 1997).

The C. rectus GroEL-like protein is a 64 kDa protein with antigenic properties (Hinode et al., 1998). It was found to cross-react with antibodies against human heat shock protein 60, Helicobacter pylori whole cells and the GroEL-like protein from Actinobacillus actinomycetemcomitans, a bacterial species that is associated with localized aggressive periodontitis (Hinode et al., 1998, 2002; Tanabe et al., 2003; Henderson et al., 2010). The C. rectus GroEL-like protein is also able to stimulate the production of IL-6 and IL-8 from the human gingival fibroblast monolayer (Hinode et al., 1998). The C. rectus GroEL-like protein is also found to possess immunodominant epitopes within both amino and carboxyl termini, and it may share same carboxyl epitopes with the C. rectus surface-layer (S-layer) protein (Hinode et al., 2002).

The S-layer is a monomolecular layer of a single secreted protein surrounding the entire surface which is found in almost all archaea and some Gram-positive and Gram-negative bacteria (Konstantinov et al., 2008). The S-layer protein (SLP) in C. fetus and C. rectus have been previously characterized, and the gene encoding SLP is also carried by C. showae (Tay et al., 2013). The C. rectus SLP has a molecular weight ranging between 130 and 166 kDa (Kobayashi et al., 1993; Nitta et al., 1997). C. rectus strains expressing SLP are resistant to complement and phagocytic mediated killing in the absence of specific antibodies (Okuda et al., 1997). However, C. rectus SLP does not play a major role in bacterial adhesion. C. rectus strains lacking the crsA gene which encodes the SLP protein are less effective at adhering to Hep-2 oral epithelial cells, with CrsA+ cells only 30 to 50% more adherent than the CrsA- cells (Wang et al., 2000). The CrsA- cells exhibit no difference in inducing the production of IL-6, IL-8, and TNF-α in Hep-2 cells as compared with CrsA+ cells. However, CrsA- C. rectus strains induce higher levels of these cytokines at early time points of the infection, suggesting that the S-layer in C. rectus may facilitate bacterial survival at the site of infection by delaying the cytokine responses (Wang et al., 2000).

Macrolides are a class of antibiotics used to treat a wide variety of infections (Hirsch et al., 2012). It inhibits protein synthesis by acting on the P site of the 50S ribosomal subunit, thus preventing peptide elongation (Payot et al., 2006). The rRNA methylase enzyme encoded by the erythromycin ribosome methylase (erm) gene methylates a single adenine in the 23S component of the 50S subunit, which sterically hinders the proper interaction between the macrolide and the 50S subunit, providing antibiotic resistance (Weisblum, 1995). C. rectus is the only Campylobacter species that has the erm determinants described. These determinants include Erm B, Erm C, Erm F, and Erm Q, though their clinical implications have not been examined (Roe et al., 1995).

In addition to its role in periodontal disease, C. rectus has been implicated in the association between maternal periodontitis and adverse pregnancy outcomes. Madianos et al. reported that a significantly elevated level of fetal IgM to C. rectus was observed among premature infants as compared to full-term neonates, indicating that C. rectus, as a maternal oral pathogen, may act as a primary infectious agent in fetus that leads to prematurity (Madianos et al., 2001). Later study by the same group demonstrated that C. rectus mediated growth restriction in a pregnant mice model, as higher numbers of growth-restricted fetuses were observed in the groups subcutaneously challenged by C. rectus as compared to the non-challenged groups (Yeo et al., 2005). The same group also showed that maternal C. rectus infection increased fetal brain expression of proinflammatory cytokines IFN-γ (Offenbacher et al., 2005). Furthermore, Arce and colleagues demonstrated that C. rectus was more invasive to human trophoblasts as compared to C. jejuni, paralleled with significantly upregulated mRNA and protein expressions of IL-6 and TNF-α in a dose-dependent manner (Arce et al., 2010). Moreover, the study also showed that C. rectus was able to translocate in vivo from a distant site of infection to the fetoplacental unit (Arce et al., 2010). Taking together, these studies suggest that as a pathogen in the oral cavity, C. rectus has the potential to contribute to the adverse pregnancy outcomes.

C. ureolyticus

C. ureolyticus (formally known as Bacteroides ureolyticus) was first described in 1978 by Jackson et al., the strain was isolated from amniotic fluid using anaerobic condition (Jackson and Goodman, 1978). A later study has isolated C. ureolyticus from 103 superficial necrotic or gangrenous lesions. However, C. ureolyticus was rarely the sole bacterial species isolated from the site of infections, suggesting other microorganisms may be responsible for the pathogenesis of these diseases (Duerden et al., 1982).

C. ureolyticus has been frequently isolated from the genital tracts of both male and female. By examining the whole cell proteins of C. ureolyticus strains, Akhtar and Eley showed that strains isolated from urethra of men with and without non-gonococcal urethritis showed no difference in SDS-PAGE patterns (Akhtar and Eley, 1992). Later studies by Bennett et al. reported that C. ureolyticus was isolated from healthy individuals at a similar prevalence as compared with that from males and females presenting non-gonococcal urethritis (Bennett et al., 1990, 1991). These results indicate that C. ureolyticus is a part of the normal flora in the genital tract of both male and female.

In the past decades, C. ureolyticus has been considered as an emergent Campylobacter species in gastroenteritis as it is frequently isolated from fecal samples of patients presenting with diarrheal illness. By using a multiplex-PCR systems, Bullman et al. first reported the isolation of C. ureolyticus from feces of patients with gastroenteritis. Among all the Campylobacter positive samples being screened, 24% (83/349) was found to be positive for C. ureolyticus, of which 64% (53/83) had C. ureolycitus as the sole Campylobacter species detected (Bullman et al., 2011). By using PCR methods, another study by Bullman et al. also found that C. ureolyticus was the second most common non-C. jejuni/C. coli species in fecal samples collected from patients presenting diarrheal illness (Bullman et al., 2012). However, healthy controls were not included in these studies.

By combining the bacterial isolation and molecular detection methods, Collado et al. reported that C. ureolyticus is the third most prevalent species of the Campylobacteria family in diarrheic stool samples in addition to C. concisus and C. jejuni, but no statistical difference was found between the diarrheic and healthy groups (Collado et al., 2013). A recent study has also reported the detection of C. ureolyticus from traveler's diarrhea cases (Serichantalergs et al., 2017). This study showed that C. ureolyticus was detected at a similar prevalence in patients presenting diarrhea and healthy individuals.

Despite being frequently isolated or detected from diarrheal stool samples, the association between C. ureolyticus and diarrheal diseases has not been established. However, the pathogenic potentials of C. ureolyticus have been examined by a number of in vitro studies. Through whole genome sequencing of C. ureolyticus strains, genes encoding known virulence factors have been identified. These factors were involved in bacterial adhesion, colonization, invasion, and toxin production (Bullman et al., 2013). By using an intestinal epithelial cell line model, C. ureolyticus was shown to be capable of adhering to Caco-2 cells but unable to invade, with the bacterial adhesion followed by cellular damage and microvillus degradation. Furthermore, secretome analysis had also detected release of putative virulence and colonization factors (Burgos-Portugal et al., 2012).

Hariharan et al. reported the isolation of C. ureolyticus from endometria of apparently normal mares under anaerobic condition (Hariharan et al., 1994). So far, this is the only study has reported isolation of C. ureolyticus from animal sources.

C. gracilis

C. gracilis (formally known as Bacteroides gracilis) was first isolated by Tanner et al. in 1981 from patients with gingivitis and periodontitis (Tanner et al., 1981).

C. gracilis has been isolated from patients with periodontal and endodontic infections, however its pathogenetic role in these diseases is still controversial. Macuch et al. reported that in addition to C. rectus, C. gracilis was the most dominant Campylobacter species isolated from subgingival sites among eight Campylobacter species being examined. However, similar levels of C. gracilis were detected in healthy, gingivitis and periodontitis sites, suggesting that its prevalence or quantity was unrelated to periodontal health or disease (Macuch and Tanner, 2000). A study by Siqueira and Rocas examining the prevalence of C. gracilis in patients with primary endodontic infections also found that it was not associated with clinical symptoms of the diseases (Siqueira and Rocas, 2003).

The first complete genome of C. gracilis was sequenced by Miller et al., which lead to identification of genes encoding for virulence factors including haemagglutinins, Zot, immunity proteins and other putative pathogenic factors (Miller and Yee, 2015). Nevertheless, supporting evidence for the virulence of C. gracilis is still lacking.

C. showae, C. hominis, and C. curvus

C. showae was first isolated by Etoh et al. in 1993 from dental plaque of gingival crevices of healthy adults (Etoh et al., 1993). A study later by Macuch et al. examining the prevalence of oral Campylobacter species from subgingival sites showed that in addition to C. rectus, C. showae was also found more frequently and in higher levels from patients with periodontitis and gingivitis than from healthy controls (Macuch and Tanner, 2000).

C. hominis was first described in 1998 by Lawson et al. through Campylobacter specific PCR assays. C. hominis was detected from stool samples of 50% of the 20 healthy individuals, while it was absent in all the saliva samples of the same individuals (Lawson et al., 1998). Later in a study by Lawson et al., C. hominis was isolated from the fecal samples of healthy individuals (Lawson et al., 2001).

By using PCR methods targeting the Campylobacter 16S rRNA gene, C. showae and C. hominis have been detected from intestinal biopsy samples collected from macroscopically inflamed and noninflamed areas. Furthermore, this was the first study reported the isolation of C. concisus, C. showae, C ureolyticus, and C. hominis from intestinal biopsies (Zhang et al., 2009). A later study by Man et al. also detected C. showae and C. hominis from stool specimens collected from children with CD (Man et al., 2010b). However, no association was found between the prevalence of C. showae and C. hominis in patients with CD and healthy controls.

C. curvus (previously named as Wolinella curva) was first described in 1984 by Tanner et al. (Tanner et al., 1984). C. curvus is a rarely encountered Campylobacter species in humans. Lastovica et al. reported an isolation rate of C. curvus as low as 0.05% (2/4122) from diarrheic stools of pediatric patients (Lastovica and Roux, 2000). A study by Abbott et al. also isolated C curvus from stool samples and showed that the prevalence of C. curvus was associated with sporadic and outbreak of bloody gastroenteritis and Brainerd's diarrhea in Northern California (Abbott et al., 2005). There was one study which reported isolation of C. curvus and C. upsaliensis from stools of patients with Guillain-Barré syndrome and Fisher's syndrome (Koga et al., 1999). However, serological examination of the patient from whom C. curvus has been isolated did not detect antibodies to this bacterium.

Conclusion

Accumulated evidence from the past decade supports the role of human hosted C. concisus in the development of IBD and possibly Barrett's esophagus and GERD. Recently, a CD-associated C. concisus molecular marker csep1-6bpi has been identified, strongly suggests that csep1-6bpi positive C. concisus strains is a potential causative agent of human CD. In addition to C. concisus, the association between human hosted C. rectus and periodontal diseases has also been established.

Statements

Author contributions

FL played the major role in writing the review. LZ, RM, and YW provided critical feedback and helped in editing the manuscript.

Funding

This work is supported by a Faculty Research Grant awarded to LZ from the University of New South Wales (Grant No.: PS46772).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

    Abbreviations

  • 5-ASA

    5-aminosalicylic acid

  • AZA

    azathioprine

  • CD

    Crohn's disease

  • CFU

    colony forming unit

  • COX

    cyclooxygenase

  • Erm

    erythromycin ribosome methylase

  • GERD

    gastroesophageal reflux disease

  • GS

    genomospecies

  • IBD

    inflammatory bowel disease

  • IFN

    interferon

  • IL

    interleukin

  • LPS

    lipopolysaccharide

  • MP

    mercaptopurine

  • NF-κB

    nuclear factor kappa-light-chain-enhancer of activated B cells

  • PCR

    polymerase chain reaction

  • PLA2

    phospholipase A2

  • TLR

    toll-like receptor

  • TNF

    tumor necrosis factor

  • UC

    ulcerative colitis

  • Zot

    zonula occludes toxin.

References

  • 1

    Aabenhus R. Permin H. Andersen L. P. (2005). Characterization and subgrouping of Campylobacter concisus strains using protein profiles, conventional biochemical testing and antibiotic susceptibility. Eur. J. Gastroenterol. Hepatol.17, 10191024. 10.1097/00042737-200510000-00003

  • 2

    Aabenhus R. Stenram U. Andersen L. P. Permin H. Ljungh A. (2008). First attempt to produce experimental Campylobacter concisus infection in mice. World J. Gastroenterol.14, 69546959. 10.3748/wjg.14.6954

  • 3

    Abbott S. L. Waddington M. Lindquist D. Ware J. Cheung W. Ely J. et al . (2005). Description of Campylobacter curvus and C. curvus-like strains associated with sporadic episodes of bloody gastroenteritis and Brainerd's diarrhea. J. Clin. Microbiol.43, 585588. 10.1128/JCM.43.2.585-588.2005

  • 4

    Akhtar N. Eley A. (1992). Restriction endonuclease analysis and ribotyping differentiate genital and nongenital strains of Bacteroides ureolyticus. J. Clin. Microbiol.30, 24082414.

  • 5

    Alfredson D. A. Korolik V. (2007). Antibiotic resistance and resistance mechanisms in Campylobacter jejuni and Campylobacter coli. FEMS Microbiol. Lett.277, 123132. 10.1111/j.1574-6968.2007.00935.x

  • 6

    Arce R. Á. Diaz P. Barros S. Galloway P. Bobetsis Y. Threadgill D. et al . (2010). Characterization of the invasive and inflammatory traits of oral Campylobacter rectus in a murine model of fetoplacental growth restriction and in trophoblast cultures. J. Reprod. Immunol.84, 145153. 10.1016/j.jri.2009.11.003

  • 7

    Bennett K. Eley A. Woolley P. (1991). Isolation of Bacteroides ureolyticus from the female genital tract. Eur. J. Clin. Microbiol. Infect. Dis.10, 593594. 10.1007/BF01967281

  • 8

    Bennett K. Eley A. Woolley P. Duerden B. (1990). Isolation of Bacteroides ureolyticus from the genital tract of men with and without non-conococcal urethritis. Eur. J. Clin. Microbiol. Infect. Dis.9, 825826. 10.1007/BF01967383

  • 9

    Bézian M. Ribou G. Barberis-Giletti C. Megraud F. (1990). Isolation of a urease positive thermophilic variant of Campylobacter lari from a patient with urinary tract infection. Eur. J. Clin. Microbiol. Infect. Dis.9, 895897. 10.1007/BF01967506

  • 10

    Blackett K. Siddhi S. Cleary S. Steed H. Miller M. Macfarlane S. et al . (2013). Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality?Aliment. Pharmacol. Ther.37, 10841092. 10.1111/apt.12317

  • 11

    Blaser M. J. Glass R. I. Huq M. I. Stoll B. Kibriya G. Alim A. (1980a). Isolation of Campylobacter fetus subsp. jejuni from Bangladeshi children. J. Clin. Microbiol.12, 744747.

  • 12

    Blaser M. J. Laforce F. M. Wilson N. A. Wang W. L. L. (1980b). Reservoirs for human Campylobacteriosis. J. Infect. Dis.141, 665669.

  • 13

    Blaser M. J. Perez G. P. Smith P. F. Patton C. Tenover F. C. Lastovica A. J. et al . (1986). Extraintestinal Campylobacter jejuni and Campylobacter coli infections: host factors and strain characteristics. J. Infect. Dis.153, 552559. 10.1093/infdis/153.3.552

  • 14

    Buelow D. R. Christensen J. E. Neal-Mckinney J. M. Konkel M. E. (2011). Campylobacter jejuni survival within human epithelial cells is enhanced by the secreted protein CiaI. ?Mol. Microbiol.80, 12961312. 10.1111/j.1365-2958.2011.07645.x

  • 15

    Bullman S. Corcoran D. O'leary J. Lucey B. Byrne D. Sleator R. D. (2011). Campylobacter ureolyticus: an emerging gastrointestinal pathogen?Pathog. Dis.61, 228230. 10.1111/j.1574-695X.2010.00760.x

  • 16

    Bullman S. Lucid A. Corcoran D. Sleator R. D. Lucey B. (2013). Genomic investigation into strain heterogeneity and pathogenic potential of the emerging gastrointestinal pathogen Campylobacter ureolyticus. PLoS ONE8:e71515. 10.1371/journal.pone.0071515

  • 17

    Bullman S. O'leary J. Corcoran D. Sleator R. Lucey B. (2012). Molecular-based detection of non-culturable and emerging campylobacteria in patients presenting with gastroenteritis. Epidemiol. Infect.140, 684688. 10.1017/S0950268811000859

  • 18

    Burgos-Portugal J. A. Kaakoush N. O. Raftery M. J. Mitchell H. M. (2012). Pathogenic potential of Campylobacter ureolyticus. Infect. Immun.80, 883890. 10.1128/IAI.06031-11

  • 19

    Campero C. M. Anderson M. Walker R. Blanchard P. Barbano L. Chiu P. et al . (2005). Immunohistochemical identification of Campylobacter fetus in natural cases of bovine and ovine abortions. Zoonoses Public Health52, 138141. 10.1111/j.1439-0450.2005.00834.x

  • 20

    Chan F. Stringel G. Mackenzie A. (1983). Isolation of Campylobacter jejuni from an appendix. J. Clin. Microbiol.18, 422424.

  • 21

    Chua K. Gürtler V. Montgomery J. Fraenkel M. Mayall B. C. Grayson M. L. (2007). Campylobacter insulaenigrae causing septicaemia and enteritis. J. Med. Microbiol.56, 15651567. 10.1099/jmm.0.47366-0

  • 22

    Chung H. K. Tay A. Octavia S. Chen J. Liu F. Ma R. et al . (2016). Genome analysis of Campylobacter concisus strains from patients with inflammatory bowel disease and gastroenteritis provides new insights into pathogenicity. Sci. Rep.6:38442. 10.1038/srep38442

  • 23

    Clevers H. (2013). The intestinal crypt, a prototype stem cell compartment. Cell154, 274284. 10.1016/j.cell.2013.07.004

  • 24

    Collado L. Gutiérrez M. González M. Fernández H. (2013). Assessment of the prevalence and diversity of emergent Campylobacteria in human stool samples using a combination of traditional and molecular methods. DMID75, 434436. 10.1016/j.diagmicrobio.2012.12.006

  • 25

    Collins M. T. Lisby G. Moser C. Chicks D. Christensen S. Reichelderfer M. et al . (2000). Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J. Clin. Microbiol.38, 43734381.

  • 26

    Control and Prevention (2006). Principles of Epidemiology in Public Health Practice: An Introduction to Applied Epidemiology and Biostatistics. Atlanta, GA: US Dept. of Health and Human Services, Centers for Disease Control and Prevention(CDC), Office of Workforce and Career Development.

  • 27

    Cortelli J. R. Aquino D. R. Cortelli S. C. Fernandes C. B. De Carvalho-Filho J. Franco G. C. N. et al . (2008). Etiological analysis of initial colonization of periodontal pathogens in oral cavity. J. Clin. Microbiol.46, 13221329. 10.1128/JCM.02051-07

  • 28

    Coventry J. Griffiths G. Scully C. Tonetti M. (2000). ABC of oral health: periodontal disease. BMJ321:36. 10.1136/bmj.321.7252.36

  • 29

    Cunningham C. Lee C. H. (2003). Myocarditis related to Campylobacter jejuni infection: a case report. BMC Infect. Dis.3:16. 10.1186/1471-2334-3-16

  • 30

    De Souza H. S. Fiocchi C. (2016). Immunopathogenesis of IBD: current state of the art. Nat. Rev. Gastroenterol. Hepatol.13:13. 10.1038/nrgastro.2015.186

  • 31

    De Vries J. Arents N. Manson W. (2008). Campylobacter species isolated from extra-oro-intestinal abscesses: a report of four cases and literature review. Eur. J. Clin. Microbiol. Infect. Dis.27, 11191123. 10.1007/s10096-008-0550-2

  • 32

    De Zoete M. R. Keestra A. M. Roszczenko P. Van Putten J. P. (2010). Activation of human and chicken toll-like receptors by Campylobacter spp. Infect. Immun.78, 12291238. 10.1128/IAI.00897-09

  • 33

    Debruyne L. Gevers D. Vandamme P. (2008). Taxonomy of the family Campylobacteraceae in Campylobacter, 3rd Edn, eds NachamkinI.BlaserM. J.SzymanskiC. M. (Washington, DC: American Society of Microbiology), 325.

  • 34

    Debruyne L. On S. L. De Brandt E. Vandamme P. (2009). Novel Campylobacter lari-like bacteria from humans and molluscs: description of Campylobacter peloridis sp. nov., Campylobacter lari subsp. concheus subsp. nov. and Campylobacter lari subsp. lari subsp. nov. Int. J. Syst. Evol. Microbiol.59, 11261132. 10.1099/ijs.0.000851-0

  • 35

    Deshpande N. P. Wilkins M. R. Castano-Rodriguez N. Bainbridge E. Sodhi N. Riordan S. M. et al . (2016). Campylobacter concisus pathotypes induce distinct global responses in intestinal epithelial cells. Sci Rep6:34288. 10.1038/srep34288

  • 36

    Dhawan V. K. Ulmer D. D. Rao B. See R. C. Nachum R. (1986). Campylobacter jejuni septicemia-epidemiology, clinical features and outcome. West. J. Med.144:324.

  • 37

    Di Pilato V. Freschi G. Ringressi M. N. Pallecchi L. Rossolini G. M. Bechi P. (2016). The esophageal microbiota in health and disease. Ann. N. Y. Acad. Sci.1381, 2133. 10.1111/nyas.13127

  • 38

    Dibart S. Skobe Z. Snapp K. Socransky S. Smith C. Kent R. (1998). Identification of bacterial species on or in crevicular epithelial cells from healthy and periodontally diseased patients using DNA-DNA hybridization. Mol. Oral Microbiol.13, 3035. 10.1111/j.1399-302X.1998.tb00747.x

  • 39

    D'Incà R. Annese V. Di Leo V. Latiano A. Quaino V. Abazia C. et al . (2006). Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment. Pharmacol. Ther.23, 14551461. 10.1111/j.1365-2036.2006.02916.x

  • 40

    Dongari-Bagtzoglou A. Ebersole J. (1996). Production of inflammatory mediators and cytokines by human gingival fibroblasts following bacterial challenge. J. Periodont. Res.31, 9098. 10.1111/j.1600-0765.1996.tb00469.x

  • 41

    Duerden B. Bennet K. Faulkner J. (1982). Isolation of Bacteroides ureolyticus (B corrodens) from clinical infections. J. Clin. Pathol.35, 309312. 10.1136/jcp.35.3.309

  • 42

    Duerden B. Eley A. Goodwin L. Magee J. Hindmarch J. Bennett K. (1989). A comparison of Bacteroides ureolyticus isolates from different clinical sources. J. Med. Microbiol.29, 6373. 10.1099/00222615-29-1-63

  • 43

    Duerden B. Goodwin L. O'neil T. (1987). Identification of Bacteroides species from adult periodontal disease. J. Med. Microbiol.24, 133137. 10.1099/00222615-24-2-133

  • 44

    Eaves-Pyles T. Murthy K. Liaudet L. Virág L. Ross G. Soriano F. G. et al . (2001). Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: IκBα degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. J. Immunol.166, 12481260. 10.4049/jimmunol.166.2.1248

  • 45

    Edmonds P. Patton C. Barrett T. Morris G. Steigerwalt A. Brenner D. (1985). Biochemical and genetic characteristics of atypical Campylobacter fetus subsp. fetus strains isolated from humans in the United States. J. Clin. Microbiol.21, 936940.

  • 46

    Edmonds P. Patton C. Griffin P. Barrett T. Schmid G. Baker C. et al . (1987). Campylobacter hyointestinalis associated with human gastrointestinal disease in the United States. J. Clin. Microbiol.25, 685691.

  • 47

    Engberg J. Bang D. D. Aabenhus R. Aarestrup F. M. Fussing V. Gerner-Smidt P. (2005). Campylobacter concisus: an evaluation of certain phenotypic and genotypic characteristics. Clin. Microbiol. Infect.11, 288295. 10.1111/j.1469-0691.2005.01111.x

  • 48

    Etoh Y. Dewhirst F. Paster B. Yamamoto A. Goto N. (1993). Campylobacter showae sp. nov., isolated from the human oral cavity. Int. J. Syst. Evol. Microbiol.43, 631639. 10.1099/00207713-43-4-631

  • 49

    Fasano A. Baudry B. Pumplin D. W. Wasserman S. S. Tall B. D. Ketley J. M. et al . (1991). Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc. Natl. Acad. Sci. U.S.A.88, 52425246. 10.1073/pnas.88.12.5242

  • 50

    Fennell C. Rompalo A. Totten P. Bruch K. Flores B. Stamm W. (1986). Isolation of “Campylobacter hyointestinalis” from a human. J. Clin. Microbiol.24, 146148.

  • 51

    Figura N. Guglielmetti P. Zanchi A. Partini N. Armellini D. Bayeli P. F. et al . (1993). Two cases of Campylobacter mucosalis enteritis in children. J. Clin. Microbiol.31, 727728.

  • 52

    Fox E. M. Raftery M. Goodchild A. Mendz G. L. (2007). Campylobacter jejuni response to ox-bile stress. FEMS Immunol. Med. Microbiol.49, 165172. 10.1111/j.1574-695X.2006.00190.x

  • 53

    Francioli P. Herzstein J. Grob J.-P. Vallotton J.-J. Mombelli G. Glauser M. P. (1985). Campylobacter fetus subspecies fetus bacteremia. Arch. Intern. Med.145, 289292. 10.1001/archinte.1985.00360020125020

  • 54

    Fujihara N. Takakura S. Saito T. Iinuma Y. Ichiyama S. (2006). A case of perinatal sepsis by Campylobacter fetus subsp. fetus infection successfully treated with carbapenem–case report and literature review. J. Infect.53, e199e202. 10.1016/j.jinf.2006.01.009

  • 55

    Galanis E. (2007). Campylobacter and bacterial gastroenteritis. CMAJ177, 570571. 10.1503/cmaj.070660

  • 56

    Garcia M. M. Lutze-Wallace C. L. Denes A. S. Eaglesome M. D. Holst E. Blaser M. J. (1995). Protein shift and antigenic variation in the S-layer of Campylobacter fetus subsp. venerealis during bovine infection accompanied by genomic rearrangement of sapA homologs. J. Bacteriol.177, 19761980. 10.1128/jb.177.8.1976-1980.1995

  • 57

    Gewirtz A. T. Navas T. A. Lyons S. Godowski P. J. Madara J. L. (2001). Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol.167, 18821885. 10.4049/jimmunol.167.4.1882

  • 58

    Gilbert G. Davoren R. Cole M. Radford N. (1981). Midtrimester abortion associated with septicaemia caused by Campylobacter jejuni. Med. J. Aust.1, 585586.

  • 59

    Gmur R. Guggenheim B. (1994). Interdental supragingival plaque—a natural habitat of Actinobacillus actinomycetemcomitans, Bacteroides forsythus, Campylobacter rectus, and Prevotella nigrescens. J. Dent. Res.73, 14211428. 10.1177/00220345940730080501

  • 60

    Goossens H. Kremp L. Boury R. Vlaes L. Van Den Borre C. Henocque G. et al . (1986). Nosocomial outbreak of Campylobacter jejuni meningitis in newborn infants. Lancet328, 146149. 10.1016/S0140-6736(86)91956-2

  • 61

    Gorkiewicz G. Feierl G. Zechner R. Zechner E. L. (2002). Transmission of Campylobacter hyointestinalis from a pig to a human. J. Clin. Microbiol.40, 26012605. 10.1128/JCM.40.7.2601-2605.2002

  • 62

    Greenstein R. J. Su L. Haroutunian V. Shahidi A. Brown S. T. (2007). On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. PLoS ONE2:e161. 10.1371/journal.pone.0000161

  • 63

    Gurgan T. Diker K. S. (1994). Abortion associated with Campylobacter upsaliensis. J. Clin. Microbiol.32, 30933094.

  • 64

    Hagiya H. Ogawa H. Takahashi Y. Hasegawa K. Hanayama Y. Otsuka F. (2015). Infective internal iliac artery aneurysm caused by Campylobacter fetus. Intern. Med.54, 20212024. 10.2169/internalmedicine.54.4845

  • 65

    Han X. Y. Tarrand J. J. Rice D. C. Han X. Y. Tarrand J. J. Rice D. C. (2005). Oral Campylobacter species involved in extraoral abscess : a report of three cases. J. Clin. Microbiol.43, 25132515. 10.1128/JCM.43.5.2513-2515.2005

  • 66

    Hanauer S. B. (2006). Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment. Pharmacol. Ther.24(Suppl. 3), 3740. 10.1111/j.1365-2036.2006.03058.x

  • 67

    Hannu T. Kauppi M. Tuomala M. Laaksonen I. Klemets P. Kuusi M. (2004). Reactive arthritis following an outbreak of Campylobacter jejuni infection. J. Rheumatol.31, 528530.

  • 68

    Hannu T. Mattila L. Rautelin H. Pelkonen P. Lahdenne P. Siitonen A. et al . (2002). Campylobacter-triggered reactive arthritis: a population-based study. Rheumatology41, 312318. 10.1093/rheumatology/41.3.312

  • 69

    Hariharan H. Richardson G. Homey B. Heaney S. Bryenton J. Moore I. (1994). Isolation of Bacteroides ureolyticus from the equine endometrium. J. Vet. Diagn. Investig.6, 127130. 10.1177/104063879400600130

  • 70

    Haydon D. T. Cleaveland S. Taylor L. H. Laurenson M. K. (2002). Identifying reservoirs of infection: a conceptual and practical challenge. Emerg. Infect. Dis.8, 14681473. 10.3201/eid0812.010317

  • 71

    Henderson B. Ward J. M. Ready D. (2010). Aggregatibacter (Actinobacillus) actinomycetemcomitans: a triple A* periodontopathogen?Periodontol 2000 54, 78105. 10.1111/j.1600-0757.2009.00331.x

  • 72

    Hidaka N. Maeda K. Kawakami C. Aono M. Okada H. (1981). Fibrinolytic activity in periodontal disease: the relationship between fibrinolytic activity and severity of periodontal disease. J. Periodontol.52, 181186. 10.1902/jop.1981.52.4.181

  • 73

    Highfield J. (2009). Diagnosis and classification of periodontal disease. Aust. Dent. J.54, S11S26. 10.1111/j.1834-7819.2009.01140.x

  • 74

    Hinode D. Yokoyama M. Tanabe S. Yoshioka M. Nakamura R. (2002). Antigenic properties of the GroEL-like protein of Campylobacter rectus. Mol. Oral Microbiol.17, 1621. 10.1046/j.0902-0055.2001.00086.x

  • 75

    Hinode D. Yoshioka M. Tanabe S.-I. Miki O. Masuda K. Nakamura R. (1998). The GroEL-like protein from Campylobacter rectus: immunological characterization and interleukin-6 and-8 induction in human gingival fibroblast. FEMS Microbiol. Lett.167, 16. 10.1111/j.1574-6968.1998.tb13199.x

  • 76

    Hirsch R. Deng H. Laohachai M. (2012). Azithromycin in periodontal treatment: more than an antibiotic. J. Periodont. Res.47, 137148. 10.1111/j.1600-0765.2011.01418.x

  • 77

    Hollander D. Vadheim C. M. Brettholz E. Petersen G. M. Delahunty T. Rotter J. I. (1986). Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann. Intern. Med.105, 883885. 10.7326/0003-4819-105-6-883

  • 78

    Horio Y. Shiraishi Y. Watanabe N. Inoue S. Imanishi T. Asano K. (2017). Empyema associated with Campylobacter curvus infection. Respirol Case Rep5:e00234. 10.1002/rcr2.234

  • 79

    Huq M. Van T. T. H. Gurtler V. Elshagmani E. Allemailem K. S. Smooker P. M. et al . (2017). The ribosomal RNA operon (rrn) of Campylobacter concisus supports molecular typing to genomospecies level. Gene Rep.6, 814. 10.1016/j.genrep.2016.10.008

  • 80

    Ichiyama S. Hirai S. Minami T. Nishiyama Y. Shimizu S. Shimokata K. et al . (1998). Campylobacter fetus subspecies fetus cellulitis associated with bacteremia in debilitated hosts. Clin. Infect. Dis.27, 252255. 10.1086/514654

  • 81

    Iovine N. M. (2013). Resistance mechanisms in Campylobacter jejuni. Virulence4, 230240. 10.4161/viru.23753

  • 82

    Irvine E. J. Marshall J. K. (2000). Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology119, 17401744. 10.1053/gast.2000.20231

  • 83

    Irwin C. Myrillas T. (1998). The role of IL-6 in the pathogenesis of periodontal disease. Oral Dis.4, 4347. 10.1111/j.1601-0825.1998.tb00255.x

  • 84

    Ismail Y. Lee H. Riordan S. M. Grimm M. C. Zhang L. (2013). The effects of oral and enteric Campylobacter concisus strains on expression of TLR4, MD-2, TLR2, TLR5 and COX-2 in HT-29 cells. PLoS ONE8:e56888. 10.1371/journal.pone.0056888

  • 85

    Ismail Y. Mahendran V. Octavia S. Day A. S. Riordan S. M. Grimm M. C. et al . (2012). Investigation of the enteric pathogenic potential of oral Campylobacter concisus strains isolated from patients with inflammatory bowel disease. PLoS ONE7:e38217. 10.1371/journal.pone.0038217

  • 86

    Istivan T. (2005). Molecular Characterisation of Campylobacter concisus: A Potential Etiological Agent of Gastroenteritis in Children. School of Applied Sciences, RMIT University.

  • 87

    Istivan T. S. Coloe P. J. Fry B. N. Ward P. Smith S. C. (2004). Characterization of a haemolytic phospholipase A(2) activity in clinical isolates of Campylobacter concisus. J. Med. Microbiol.53, 483493. 10.1099/jmm.0.45554-0

  • 88

    Jackson F. L. Goodman Y. E. (1978). Bacteroides ureolyticus, a new species to accommodate strains previously identified as “Bacteroides corrodens, anaerobic”. Int. J. Syst. Bacteriol.28, 197200. 10.1099/00207713-28-2-197

  • 89

    Jimenez S. G. Heine R. G. Ward P. B. Robins-Browne R. M. (1999). Campylobacter upsaliensis gastroenteritis in childhood. Pediatr. Infect. Dis. J.18, 988992. 10.1097/00006454-199911000-00011

  • 90

    Johnson C. C. Reinhardt J. F. Mulligan M. E. George W. L. Finegold S. M. (1986). In vitro activities of 17 antimicrobial agents against the formate/fumarate-requiring, anaerobic gram-negative bacilli. DMID5, 269272. 10.1016/0732-8893(86)90011-8

  • 91

    Johnson C. C. Reinhardt J. Edelstein M. Mulligan M. George W. Finegold S. (1985). Bacteroides gracilis, an important anaerobic bacterial pathogen. J. Clin. Microbiol.22, 799802.

  • 92

    Kaakoush N. O. Deshpande N. P. Man S. M. Burgos-Portugal J. A. Khattak F. A. Raftery M. J. et al . (2015). Transcriptomic and proteomic analyses reveal key innate immune signatures in the host response to the gastrointestinal pathogen Campylobacter concisus. Infect. Immun.83, 832845. 10.1128/IAI.03012-14

  • 93

    Kaakoush N. O. Deshpande N. P. Wilkins M. R. Raftery M. J. Janitz K. Mitchell H. (2011). Comparative analyses of Campylobacter concisus strains reveal the genome of the reference strain BAA-1457 is not representative of the species. Gut Pathog.3, 1515. 10.1186/1757-4749-3-15

  • 94

    Kalischuk L. Inglis G. (2011). Comparative genotypic and pathogenic examination of Campylobacter concisus isolates from diarrheic and non-diarrheic humans. BMC Microbiol.11:53. 10.1186/1471-2180-11-53

  • 95

    Kirk K. F. Méric G. Nielsen H. L. Pascoe B. Sheppard S. K. Thorlacius-Ussing O. et al . (2018). Molecular epidemiology and comparative genomics of Campylobacter concisus strains from saliva, faeces and gut mucosal biopsies in inflammatory bowel disease. Sci. Rep.8:1902. 10.1038/s41598-018-20135-4

  • 96

    Kirk K. F. Nielsen H. L. Thorlacius-Ussing O. Nielsen H. (2016). Optimized cultivation of Campylobacter concisus from gut mucosal biopsies in inflammatory bowel disease. Gut Pathog.8:27. 10.1186/s13099-016-0111-7

  • 97

    Kist M. Keller K.-M. Niebling W. Kilching W. (1984). Campylobacter coli septicaemia associated with septic abortion. Infection12, 8890. 10.1007/BF01641678

  • 98

    Klein B. S. Vergeront J. M. Blaser M. J. Edmonds P. Brenner D. J. Janssen D. et al . (1986). Campylobacter infection associated with raw milk: an outbreak of gastroenteritis due to Campylobacter jejuni and thermotolerant Campylobacter fetus subsp fetus. JAMA255, 361364. 10.1001/jama.1986.03370030081032

  • 99

    Knights D. Lassen K. G. Xavier R. J. (2013). Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut62, 15051510. 10.1136/gutjnl-2012-303954

  • 100

    Kobayashi Y. Ohta H. Kokeguchi S. Murayama Y. Kato K. Kurihara H. et al . (1993). Antigenic properties of Campylobacter rectus (Wolinella recta) major S-layer proteins. FEMS Microbiol. Lett.108, 275280. 10.1111/j.1574-6968.1993.tb06115.x

  • 101

    Koga M. Yuki N. Takahashi M. Saito K. Hirata K. (1999). Are Campylobacter curvus and Campylobacter upsaliensis antecedent infectious agents in Guillain–Barré and Fisher's syndromes?J. Neurol. Sci.163, 5357.

  • 102

    Kohler A. De Torrenté A. Inderwildi B. (1988). Fisher's syndrome associated with Campylobacter jejuni infection. Eur. Neurol.28, 150151.

  • 103

    Könönen E. Paju S. Pussinen P. J. Hyvönen M. Di Tella P. Suominen-Taipale L. et al . (2007). Population-based study of salivary carriage of periodontal pathogens in adults. J. Clin. Microbiol.45, 24462451. 10.1128/JCM.02560-06

  • 104

    Konstantinov S. R. Smidt H. De Vos W. M. Bruijns S. C. Singh S. K. Valence F. et al . (2008). S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc. Natl. Acad. Sci. U.S.A.105, 1947419479. 10.1073/pnas.0810305105

  • 105

    Korman T. Varley C. Spelman D. (1997). Acute hepatitis associated with Campylobacter jejuni bacteraemia. Eur. J. Clin. Microbiol. Infect. Dis.16, 678681. 10.1007/BF01708559

  • 106

    Krause R. Ramschak-Schwarzer S. Gorkiewicz G. Schnedl W. Feierl G. Wenisch C. et al . (2002). Recurrent septicemia due to Campylobacter fetus and Campylobacter lari in an immunocompetent patient. Infection30, 171174. 10.1007/s15010-002-2115-0

  • 107

    Kwon S. Y. Cho D. H. Lee S. Y. Lee K. Chong Y. (1994). Antimicrobial susceptibility of Campylobacter fetus subsp. fetus isolated from blood and synovial fluid. Yonsei Med. J.35, 314319. 10.3349/ymj.1994.35.3.314

  • 108

    La Scolea L. J. (1985). Campylobacter fetus subsp. fetus meningitis in a neonate. Clin. Microbiol. Newsl.7, 125126. 10.1016/S0196-4399(85)80024-6

  • 109

    Lastovica A. J. (2006). Emerging Campylobacter spp.: the tip of the iceberg. Clin. Microbiol. Newsl.28, 4956. 10.1016/j.clinmicnews.2006.03.004

  • 110

    Lastovica A. J. Le Roux E. (2001). Efficient isolation of Campylobacter upsaliensis from stools. J. Clin. Microbiol.39, 42224223. 10.1128/JCM.39.11.4222-4223.2001

  • 111

    Lastovica A. J. Roux E. (2000). Efficient isolation of Campylobacteria from stools. J. Clin. Microbiol.38, 27982800.

  • 112

    Lastovica A. J. On S. L. Zhang L. (2014). The family Campylobacteraceae, in The Prokaryotes, eds RosenbergE.DeLongE. F.LoryS.StackebrandtE.ThompsonF. (Berlin, Heidelberg: Springer), 307335. 10.1007/978-3-642-39044-9_274

  • 113

    Lastovica A. Le Roux E. Penner J. (1989). Campylobacter upsaliensis” isolated from blood cultures of pediatric patients. J. Clin. Microbiol.27, 657659.

  • 114

    Lavrencic P. Kaakoush N. O. Huinao K. D. Kain N. Mitchell H. M. (2012). Investigation of motility and biofilm formation by intestinal Campylobacter concisus strains. Gut Pathog.4, 2222. 10.1186/1757-4749-4-22

  • 115

    Lawson A. J. Linton D. Stanley J. (1998). 16S rRNA gene sequences of ‘Candidatus Campylobacter hominis’, a novel uncultivated species, are found in the gastrointestinal tract of healthy humans. Microbiology144, 20632071.

  • 116

    Lawson A. J. On S. Logan J. Stanley J. (2001). Campylobacter hominis sp. nov., from the human gastrointestinal tract. Int. J. Syst. Evol. Microbiol.51, 651660. 10.1099/00207713-51-2-651

  • 117

    Lawson A. Linton D. Stanley J. Owen R. (1997). Polymerase chain reaction detection and speciation of Campylobacter upsaliensis and C. helveticus in human faeces and comparison with culture techniques. J. Appl. Microbiol.83, 375380. 10.1046/j.1365-2672.1997.00240.x

  • 118

    Lee H. Ma R. Grimm M. C. Riordan S. M. Lan R. Zhong L. et al . (2014). Examination of the anaerobic growth of Campylobacter concisus strains. Int. J. Microbiol.2014:476047. 10.1155/2014/476047

  • 119

    Lee H.-J. Kim J.-K. Cho J.-Y. Lee J.-M. Hong S.-H. (2012). Quantification of subgingival bacterial pathogens at different stages of periodontal diseases. Curr. Microbiol.65, 2227. 10.1007/s00284-012-0121-8

  • 120

    Leo Q. J. N. Bolger D. T. (2014). Septic cavernous sinus thrombosis due to Campylobacter rectus infection. BMJ Case Rep.2014:bcr2013203351. 10.1136/bcr-2013-203351

  • 121

    Lindblom G. Sjogren E. Hansson-Westerberg J. Kaijser B. (1995). Campylobacter upsaliensis, C. sputorum sputorum and C. concisus as common causes of diarrhoea in Swedish children. Scand. J. Infect. Dis.27, 187188. 10.3109/00365549509019006

  • 122

    Linscott A. J. Flamholtz R. B. Shukla D. Song Y. Liu C. Finegold S. M. (2005). Fatal septicemia due to Clostridium hathewayi and Campylobacter hominis. Anaerobe11, 9798. 10.1016/j.anaerobe.2004.10.002

  • 123

    Liu F. Lee H. Lan R. Zhang L. (2016). Zonula occludens toxins and their prophages in Campylobacter species. Gut Pathog.8:43. 10.1186/s13099-016-0125-1

  • 124

    Liu F. Ma R. Riordan S. M. Grimm M. C. Liu L. Wang Y. et al . (2017). Azathioprine, mercaptopurine, and 5-aminosalicylic acid affect the growth of IBD-associated Campylobacter species and other enteric microbes. Front. Microbiol.8:527. 10.3389/fmicb.2017.00527

  • 125

    Liu F. Ma R. Tay C. Y. A. Octavia S. Lan R. Chung H. K. L. et al . (2018). Genomic analysis of oral Campylobacter concisus strains identified a potential bacterial molecular marker associated with active Crohn's disease. Emerg. Microbes Infect.7:64. 10.1038/s41426-018-0065-6

  • 126

    Liu Y.-H. Yamazaki W. Huang Y.-T. Liao C.-H. Sheng W.-H. Hsueh P.-R. (2017). Clinical and microbiological characteristics of patients with bacteremia caused by Campylobacter species with an emphasis on the subspecies of C. fetus. J. Microbiol. Immunol. Infect. 10.1016/j.jmii.2017.07.009. [Epub ahead of print].

  • 127

    Logan J. Burnens A. Linton D. Lawson A. Stanley J. (2000). Campylobacter lanienae sp. nov., a new species isolated from workers in an abattoir. Int. J. Syst. Evol. Microbiol.50, 865872. 10.1099/00207713-50-2-865

  • 128

    López R. Dahlén G. Retamales C. Baelum V. (2011). Clustering of subgingival microbial species in adolescents with periodontitis. Eur. J. Oral Sci. 119, 141150. 10.1111/j.1600-0722.2011.00808.x

  • 129

    Luangtongkum T. Jeon B. Han J. Plummer P. Logue C. M. Zhang Q. (2009). Antibiotic resistance in Campylobacter: emergence, transmission and persistence. Future Microbiol.4, 189200. 10.2217/17460913.4.2.189

  • 130

    Lumerman H. Freedman P. Kerpel S. (1995). Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.79, 321329. 10.1016/S1079-2104(05)80226-4

  • 131

    Ma R. Liu F. Yap S. F. Lee H. Leong R. W. Riordan S. et al . (2018). The growth and protein expression of inflammatory bowel disease-associated Campylobacter concisus is affected by the derivatives of the food additive fumaric acid. Front. Microbiol.9:896. 10.3389/fmicb.2018.00896

  • 132

    Ma R. Sapwell N. Chung H. K. Lee H. Mahendran V. Leong R. W. et al . (2015). Investigation of the effects of pH and bile on the growth of oral Campylobacter concisus strains isolated from patients with inflammatory bowel disease and controls. J. Med. Microbiol.64, 438445. 10.1099/jmm.0.000013

  • 133

    Macfarlane S. Furrie E. Macfarlane G. T. Dillon J. F. (2007). Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. Clin. Infect. Dis.45, 2938. 10.1086/518578

  • 134

    Macuch P. Tanner A. (2000). Campylobacter species in health, gingivitis, and periodontitis. J. Dent. Res.79, 785792. 10.1177/00220345000790021301

  • 135

    Madianos P. Lieff S. Murtha A. Boggess K. Auten R. Beck J. et al . (2001). Maternal periodontitis and prematurity. Part II: maternal infection and fetal exposure. Ann. Periodontol.6, 175182. 10.1902/annals.2001.6.1.175

  • 136

    Mahendran V. Liu F. Riordan S. Grimm M. Tanaka M. Zhang L. (2016). Examination of the effects of Campylobacter concisus zonula occludens toxin on intestinal epithelial cells and macrophages. Gut Pathog.8:18. 10.1186/s13099-016-0101-9

  • 137

    Mahendran V. Octavia S. Demirbas O. F. Sabrina S. Ma R. Lan R. et al . (2015). Delineation of genetic relatedness and population structure of oral and enteric Campylobacter concisus strains by analysis of housekeeping genes. Microbiology161, 16001612. 10.1099/mic.0.000112

  • 138

    Mahendran V. Riordan S. M. Grimm M. C. Tran T. A. Major J. Kaakoush N. O. et al . (2011). Prevalence of Campylobacter species in adult Crohn's disease and the preferential colonization sites of Campylobacter species in the human intestine. PLoS ONE6:e25417. 10.1371/journal.pone.0025417

  • 139

    Mahendran V. Tan Y. S. Riordan S. M. Grimm M. C. Day A. S. Lemberg D. A. et al . (2013). The prevalence and polymorphisms of zonula occluden toxin gene in multiple Campylobacter concisus strains isolated from saliva of patients with inflammatory bowel disease and controls. PLoS ONE8:e75525. 10.1371/journal.pone.0075525

  • 140

    Mahlen S. D. Clarridge J. E. (2009). Oral abscess caused by Campylobacter rectus: case report and literature review. J. Clin. Microbiol.47, 848851. 10.1128/JCM.01590-08

  • 141

    Man S. M. Kaakoush N. O. Leach S. T. Nahidi L. Lu H. K. Norman J. et al . (2010a). Host attachment, invasion, and stimulation of proinflammatory cytokines by Campylobacter concisus and other non-Campylobacter jejuni Campylobacter species. J. Infect. Dis.202, 18551865. 10.1086/657316

  • 142

    Man S. M. Zhang L. Day A. S. Leach S. T. Lemberg D. A. Mitchell H. (2010b). Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn's disease. Inflamm. Bowel Dis.16, 10081016. 10.1002/ibd.21157

  • 143

    Manfredi R. Nanetti A. Ferri M. Chiodo F. (1999). Fatal Campylobacter jejuni bacteraemia in patients with AIDS. J. Med. Microbiol.48, 601603. 10.1099/00222615-48-6-601

  • 144

    Martel-Pelletier J. Faure M. Mccollum R. Mineau F. Cloutier J. Pelletier J. (1991). Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J. Rheumatol.18, 18631871.

  • 145

    Martinot M. Jaulhac B. Moog R. De Martino S. Kehrli P. Monteil H. et al . (2001). Campylobacter lari bacteremia. Clin. Microbiol. Infect.7, 9697. 10.1046/j.1469-0691.2001.00212.x

  • 146

    Meddings J. (2008). What role does intestinal permeability have in IBD pathogenesis?Inflamm. Bowel Dis.14(Suppl. 2), S138S139. 10.1002/ibd.20719

  • 147

    Megraud F. Tachoire C. Latrille J. Bondonny J. (1982). Appendicitis due to Campylobacter jejuni. Br. Med. J.285:1165. 10.1136/bmj.285.6349.1165-a

  • 148

    Mendz G. L. Petersen R. Quinlivan J. A. Kaakoush N. O. (2014). Potential involvement of Campylobacter curvus and Haemophilus parainfluenzae in preterm birth. BMJ Case Rep.2014:bcr2014205282. 10.1136/bcr-2014-205282

  • 149

    Meyer A. Stallmach T. Goldenberger D. Altwegg M. (1997). Lethal Maternal Sepsis Caused by Campylobacter jejuni: pathogen Preserved in Placenta and Identified by Molecular Method. Mod. Pathol.10, 12531256.

  • 150

    Miller W. G. Yee E. (2015). Complete Genome Sequence of Campylobacter gracilis ATCC 33236T. Genome Announc.3:e01087-15. 10.1128/genomeA.01087-15

  • 151

    Miller W. G. Chapman M. H. Yee E. On S. L. Mcnulty D. K. Lastovica A. J. et al . (2012). Multilocus sequence typing methods for the emerging Campylobacter species, C. hyointestinalis, C. lanienae, C. sputorum, C. concisus, and C. curvus. Front. Cell. Infect. Microbiol.2:45. 10.3389/fcimb.2012.00045

  • 152

    Møller Nielsen E. Engberg J. Madsen M. (1997). Distribution of serotypes of Campylobacter jejuni and C. coli from Danish patients, poultry, cattle and swine. FEMS Immunol. Med. Microbiol.19, 4756. 10.1111/j.1574-695X.1997.tb01071.x

  • 153

    Morooka T. Umeda A. Fujita M. Matano H. Fujimoto S. Yukitake K. et al . (1996). Epidemiologic application of pulsed-field gel electrophoresis to an outbreak of Campylobacter fetus meningitis in a neonatal intensive care unit. Scand. J. Infect. Dis.28, 269270. 10.3109/00365549609027170

  • 154

    Morris C. N. Scully B. Garvey G. J. (1998). Campylobacter lari Associated with Permanent Infection and Bacteremia. Clin. Infect. Dis.27, 220221. 10.1086/517683

  • 155

    Morrison V. A. Lloyd B. K. Chia J. K. Tuazon C. U. (1990). Cardiovascular and bacteremic manifestations of Campylobacter fetus infection: case report and review. Clin. Infect. Dis.12, 387392. 10.1093/clinids/12.3.387

  • 156

    Mortensen N. P. Kuijf M. L. Ang C. W. Schiellerup P. Krogfelt K. A. Jacobs B. C. et al . (2009). Sialylation of Campylobacter jejuni lipo-oligosaccharides is associated with severe gastro-enteritis and reactive arthritis. Microb Infect11, 988994. 10.1016/j.micinf.2009.07.004

  • 157

    Mukhopadhya I. Thomson J. M. Hansen R. Berry S. H. El-Omar E. M. Hold G. L. (2011). Detection of Campylobacter concisus and other Campylobacter species in colonic biopsies from adults with ulcerative colitis. PLoS ONE6:e21490. 10.1371/journal.pone.0021490

  • 158

    Namin B. M. Dallal M. M. S. Daryani N. E. (2015). The Effect of Campylobacter concisus on expression of IL-18, TNF-α and p53 in Barrett's cell lines. Jundishapur J. Microbiol.8:e26393. 10.5812/jjm.26393t

  • 159

    Neal-Mckinney J. M. Konkel M. E. (2012). The Campylobacter jejuni CiaC virulence protein is secreted from the flagellum and delivered to the cytosol of host cells. Front. Cell Infect. Microbiol.2:31. 10.3389/fcimb.2012.00031

  • 160

    Neuzil K. M. Wang E. Haas D. W. Blaser M. J. (1994). Persistence of Campylobacter fetus bacteremia associated with absence of opsonizing antibodies. J. Clin. Microbiol.32, 17181720.

  • 161

    Newman M. Socransky S. (1977). Predominant cultivable microbiota in periodontosis. J. Periodont. Res.12, 120128. 10.1111/j.1600-0765.1977.tb00114.x

  • 162

    Nielsen H. L. Engberg J. Ejlertsen T. Bücker R. Nielsen H. (2012). Short-term and medium-term clinical outcomes of Campylobacter concisus infection. Clin. Microbiol. Infect.18, E459465. 10.1111/j.1469-0691.2012.03990.x

  • 163

    Nielsen H. L. Nielsen H. Torpdahl M. (2016). Multilocus sequence typing of Campylobacter concisus from Danish diarrheic patients. Gut Pathog.8:44. 10.1186/s13099-016-0126-0

  • 164

    Nielsen H. L. Nielsen H. Ejlertsen T. Engberg J. Günzel D. Zeitz M. et al . (2011). Oral and fecal Campylobacter concisus strains perturb barrier function by apoptosis induction in HT-29/B6 intestinal epithelial cells. PLoS ONE6:e23858. 10.1371/journal.pone.0023858

  • 165

    Nielsen H. Ejlertsen T. Engberg J. Nielsen H. (2013). High incidence of Campylobacter concisus in gastroenteritis in North Jutland, Denmark: a population-based study. Clin. Microbiol. Infect.19, 445450. 10.1111/j.1469-0691.2012.03852.x

  • 166

    Nielsen O. H. Vainer B. Rask-Madsen J. (2001). Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment. Pharmacol. Ther.15, 16991708. 10.1046/j.1365-2036.2001.01102.x

  • 167

    Nikfar S. Rahimi R. Rezaie A. Abdollahi M. (2009). A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig. Dis. Sci.54, 11571170. 10.1007/s10620-008-0481-x

  • 168

    Nitta H. Holt S. C. Ebersole J. L. (1997). Purification and characterization of Campylobacter rectus surface layer proteins. Infect. Immun.65, 478483.

  • 169

    Noël A. Verroken A. Belkhir L. Rodriguez-Villalobos H. (2018). Fatal thoracic empyema involving Campylobacter rectus: a case report. Anaerobe49, 9598. 10.1016/j.anaerobe.2017.12.014

  • 170

    Noiri Y. Ozaki K. Nakae H. Matsuo T. Ebisu S. (1997). An immunohistochemical study on the localization of Porphyromonas gingivalis, Campylobacter rectus and Actinomyces viscosus in human periodontal pockets. J. Periodont. Res.32, 598607. 10.1111/j.1600-0765.1997.tb00937.x

  • 171

    O'doherty A. Koziel M. De Barra L. Corcoran D. Bullman S. Lucey B. et al . (2014). Development of nalidixic acid amphotericin B vancomycin (NAV) medium for the isolation of Campylobacter ureolyticus from the stools of patients presenting with acute gastroenteritis. Br. J. Biomed. Sci.71, 612. 10.1080/09674845.2014.11669956

  • 172

    Offenbacher S. Riche E. Barros S. Bobetsis Y. Lin D. Beck J. (2005). Effects of maternal Campylobacter rectus infection on murine placenta, fetal and neonatal survival, and brain development. J. Periodontol.76, 21332143. 10.1902/jop.2005.76.11-S.2133

  • 173

    Ogura N. Matsuda U. Tanaka F. Shibata Y. Takiguchi H. Abiko Y. (1996). In vitro senescence enhances IL-6 production in human gingival fibroblasts induced by lipopolysaccharide from Campylobacter rectus. Mech. Ageing Dev.87, 4759. 10.1016/0047-6374(96)01701-0

  • 174

    Ogura N. Shibata Y. Matsuda U. Oikawa T. Takiguchi H. Izumi H. et al . (1995). Effect of Campylobacter rectus LPS on plasminogen activator-plasmin system in human gingival fibroblast cells. J. Periodont. Res.30, 132140. 10.1111/j.1600-0765.1995.tb01262.x

  • 175

    Okuda K. Kigure T. Yamada S. Kaneko T. Ishihara K. Miura T. et al . (1997). Role for the S-layer of Campylobacter rectus ATCC33238 in complement mediated killing and phagocytic killing by leukocytes from guinea pig and human peripheral blood. Oral Dis.3, 113120. 10.1111/j.1601-0825.1997.tb00022.x

  • 176

    On S. Siemer B. Chung P. Lastovica A. (2013). Characterisation of Campylobacter concisus strains from South Africa using Amplified Fragment Length Polymorphism (AFLP) profiling and a Genomospecies-specific Polymerase Chain Reaction (PCR) assay: Identification of novel genomospecies and correlation with clinical data. Afr. J. Microbiol. Res.7, 18451851. 10.5897/AJMR12.2182

  • 177

    Ovesen S. Kirk K. F. Nielsen H. L. Nielsen H. (2017). Motility of Campylobacter concisus isolated from saliva, feces, and gut mucosal biopsies. APMIS125, 230235. 10.1111/apm.12655

  • 178

    Patrick M. E. Gilbert M. J. Blaser M. J. Tauxe R. V. Wagenaar J. A. Fitzgerald C. (2013). Human infections with new subspecies of Campylobacter fetus. Emerg. Infect. Dis.19, 1678. 10.3201/eid1910.130883

  • 179

    Payot S. Bolla J.-M. Corcoran D. Fanning S. Mégraud F. Zhang Q. (2006). Mechanisms of fluoroquinolone and macrolide resistance in Campylobacter spp. Microb. Infect.8, 19671971. 10.1016/j.micinf.2005.12.032

  • 180

    Pena L. A. Fishbein M. C. (2007). Fatal myocarditis related to Campylobacter jejuni infection: a case report. Cardiovasc. Pathol.16, 119121. 10.1016/j.carpath.2006.09.007

  • 181

    Petersen R. F. Harrington C. S. Kortegaard H. E. On S. L. (2007). A PCR-DGGE method for detection and identification of Campylobacter, Helicobacter, Arcobacter and related Epsilobacteria and its application to saliva samples from humans and domestic pets. J. Appl. Microbiol.103, 26012615. 10.1111/j.1365-2672.2007.03515.x

  • 182

    Pihlstrom B. L. Michalowicz B. S. Johnson N. W. (2005). Periodontal diseases. Lancet366, 18091820. 10.1016/S0140-6736(05)67728-8

  • 183

    Platts-Mills J. A. Liu J. Gratz J. Mduma E. Amour C. Swai N. et al . (2014). Detection of Campylobacter in stool and determination of significance by culture, enzyme immunoassay, and PCR in developing countries. J. Clin. Microbiol.52, 10741080. 10.1128/JCM.02935-13

  • 184

    Press A. Hauptmann I. Hauptmann L. Fuchs B. Fuchs M. Ewe K. et al . (1998). Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther.12, 673678. 10.1046/j.1365-2036.1998.00358.x

  • 185

    Pruitt K. D. Tatusova T. Maglott D. R. (2007). NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res.35, D61D65. 10.1093/nar/gkl842

  • 186

    Rams T. Feik D. Slots J. (1993). Campylobacter rectus in human periodontitis. Mol. Oral Microbiol.8, 230235. 10.1111/j.1399-302X.1993.tb00565.x

  • 187

    Reeser R. J. Medler R. T. Billington S. J. Jost B. H. Joens L. A. (2007). Characterization of Campylobacter jejuni biofilms under defined growth conditions. Appl. Environ. Microbiol.73, 19081913. 10.1128/AEM.00740-06

  • 188

    Roe D. E. Weinberg A. Roberts M. C. (1995). Mobile rRNA methylase genes in Campylobacter (Wotinella) rectus. J. Antimicrob. Chemother.36, 738740. 10.1093/jac/36.4.738

  • 189

    Roesler B. M. Rabelo-Gonçalves E. M. Zeitune J. M. (2014). Virulence factors of Helicobacter pylori: a review. Clin. Med. Insights Gastroenterol.7:9. 10.4137/CGast.S13760

  • 190

    Roop Ii R. M. Smibert R. M. Johnson J. L. Krieg N. R. (1985). DNA homology studies of the catalase-negative campylobacters and “Campylobacter fecalis,” an emended description of Campylobacter sputorum, and proposal of the neotype strain of Campylobacter sputorum. Can. J. Microbiol.31, 823831. 10.1139/m85-154

  • 191

    Samuelson D. R. Eucker T. P. Bell J. A. Dybas L. Mansfield L. S. Konkel M. E. (2013). The Campylobacter jejuni CiaD effector protein activates MAP kinase signaling pathways and is required for the development of disease. J. Cell Commun. Signal.11:79. 10.1186/1478-811X-11-79

  • 192

    Sanderson J. Moss M. Tizard M. Hermon-Taylor J. (1992). Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut33, 890896. 10.1136/gut.33.7.890

  • 193

    Sartor R. B. (2004). Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology126, 16201633. 10.1053/j.gastro.2004.03.024

  • 194

    Sauerwein R. Horrevorts A. Bisseling J. (1993). Septic abortion associated with Campylobacter fetus subspecies fetus infection: case report and review of the literature. Infection21, 331333. 10.1007/BF01712458

  • 195

    Schwartz A. G. Targan S. R. Saxon A. Weinstein W. M. (1982). Sulfasalazine-induced exacerbation of ulcerative colitis. N. Engl. J. Med.306, 409412. 10.1056/NEJM198202183060708

  • 196

    Serichantalergs O. Ruekit S. Pandey P. Anuras S. Mason C. Bodhidatta L. et al . (2017). Incidence of Campylobacter concisus and C. ureolyticus in traveler's diarrhea cases and asymptomatic controls in Nepal and Thailand. Gut Pathog.9:47. 10.1186/s13099-017-0197-6

  • 197

    Shin S. J. Collins M. T. (2008). Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob. Agents Chemother.52, 418426. 10.1128/AAC.00678-07

  • 198

    Shinha T. (2015). Fatal bacteremia caused by Campylobacter gracilis, United States. Emerg. Infect. Dis.21, 1084. 10.3201/eid2106.142043

  • 199

    Sieswerda L. E. Bannatyne R. M. (2006). Mapping the effects of genetic susceptibility and Mycobacterium avium subsp. paratuberculosis infection on Crohn's disease: strong but independent. J. Clin. Microbiol.44, 12041205. 10.1128/JCM.44.3.1204-1205.2006

  • 200

    Simor A. Karmali M. Jadavji T. Roscoe M. (1986). Abortion and perinatal sepsis associated with Campylobacter infection. Rev. Infect. Dis.8, 397402. 10.1093/clinids/8.3.397

  • 201

    Siqueira J. F. Jr. Rocas I. N. (2003). Campylobacter gracilis and Campylobacter rectus in primary endodontic infections. Int. Endod. J.36, 174180. 10.1046/j.1365-2591.2003.00636.x

  • 202

    Skirrow M. (1977). Campylobacter enteritis: a “new” disease. Br. Med. J.2, 911. 10.1136/bmj.2.6078.9

  • 203

    Smith K. D. Andersen-Nissen E. Hayashi F. Strobe K. Bergman M. A. Barrett S. L. R. et al . (2003). Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat. Immunol4:1247. 10.1038/ni1011

  • 204

    Sørensen N. B. Nielsen H. L. Varming K. Nielsen H. (2013). Neutrophil activation by Campylobacter concisus. Gut Pathog.5:17. 10.1186/1757-4749-5-17

  • 205

    Steele T. W. Sangster N. Lanser J. A. (1985). DNA relatedness and biochemical features of Campylobacter spp. isolated in central and South Australia. J. Clin. Microbiol.22, 7174.

  • 206

    Steinkraus G. E. Wright B. D. (1994). Septic abortion with intact fetal membranes caused by Campylobacter fetus subsp. fetus. J. Clin. Microbiol.32, 16081609.

  • 207

    Suzuki J. Sugiyama T. Ito K. Hadano Y. Kawamura I. Okinaka K. et al . (2013). Campylobacter showae bacteremia with cholangitis. J. Infect. Chemother.19, 960963. 10.1007/s10156-012-0524-2

  • 208

    Svensson S. L. Pryjma M. Gaynor E. C. (2014). Flagella-mediated adhesion and extracellular DNA release contribute to biofilm formation and stress tolerance of Campylobacter jejuni. PLoS ONE9:e106063. 10.1371/journal.pone.0106063

  • 209

    Takahashi M. Koga M. Yokoyama K. Yuki N. (2005). Epidemiology of Campylobacter jejuni isolated from patients with Guillain-Barré and Fisher syndromes in Japan. J. Clin. Microbiol.43, 335339. 10.1128/JCM.43.1.335-339.2005

  • 210

    Takiguchi H. Yamaguchi M. Mochizuki K. Abiko Y. (1996). Effect of in vitro aging on Campylobacter rectus lipopolysaccharide-stimulated PGE2 release from human gingival fibroblasts. Oral Dis.2, 202209. 10.1111/j.1601-0825.1996.tb00225.x

  • 211

    Takiguchi H. Yamaguchi M. Okamura H. Abiko Y. (1997). Contribution of IL-1β to the enhancement of Campylobacter rectus lipopolysaccharide-stimulated PGE 2 production in old gingival fibroblasts in vitro. Mech. Ageing Dev.98, 7590. 10.1016/S0047-6374(97)00068-7

  • 212

    Talonpoika J. Söderling E. Tiekso J. Paunio K. (1990). Gingival crevicular fluid plasmin activity in different clinical conditions and after periodontal treatment. Proc. Finn. Dent. Soc.87, 329337.

  • 213

    Tanabe S. Hinode D. Yokoyama M. Fukui M. Nakamura R. Yoshioka M. et al . (2003). Helicobacter pylori and Campylobacter rectus share a common antigen. Oral Microbiol. Immunol.18, 7987. 10.1034/j.1399-302X.2003.00049.x

  • 214

    Tanner A. C. R. Badger S. Lai C. Listgarten M. A. Visconti R. A. Socransky S. S. (1981). Wolinella gen. nov., WoZinella succinogenes (Vibrio succinogenes Wolin et al.) comb. nov., and Description of Bacteroides gracilis sp. nov., Wolinella recta sp. nov., Campylobacter concisus sp. nov., and Eikenella corrodens from Humans with Periodontal Disease. Int. J. Syst. Bacteriol. 4, 432445. 10.1099/00207713-31-4-432

  • 215

    Tanner A. Listgarten M. Ebersole J. (1984). Wolinella curva sp. nov.:“Vibrio succinogenes” of human origin. Int. J. Syst. Evol. Microbiol.34, 275282.

  • 216

    Tay A. P. Kaakoush N. O. Deshpande N. P. Chen Z. Mitchell H. Wilkins M. R. (2013). Genome sequence of Campylobacter showae UNSWCD, isolated from a patient with Crohn's disease. Genome Announc.1:e00193-12. 10.1128/genomeA.00193-12

  • 217

    Tee W. Luppino M. Rambaldo S. (1998). Bacteremia due to Campylobacter sputorum Biovar sputorum. Clin. Infect. Dis.27, 15441545. 10.1086/517748

  • 218

    Thomas K. Chan K. N. Ribeiro C. (1980). Campylobacter jejuni/coli meningitis in a neonate. BMJ280:1301. 10.1136/bmj.280.6227.1301

  • 219

    Tilmanne A. Martiny D. Hallin M. Cornelius A. Wautier M. Quach C. et al . (2018). Campylobacter concisus and acute gastroenteritis in children: lack of association. Pediatr. Infect. Dis. J. 10.1097/INF.0000000000002028. [Epub ahead of print].

  • 220

    Tu Z.-C. Dewhirst F. E. Blaser M. J. (2001). Evidence that the Campylobacter fetus sap locus is an ancient genomic constituent with origins before mammals and reptiles diverged. Infect. Immun.69, 22372244. 10.1128/IAI.69.4.2237-2244.2001

  • 221

    Tu Z.-C. Zeitlin G. Gagner J.-P. Keo T. Hanna B. A. Blaser M. J. (2004). Campylobacter fetus of reptile origin as a human pathogen. J. Clin. Microbiol.42, 44054407. 10.1128/JCM.42.9.4405-4407.2004

  • 222

    Van T. T. H. Elshagmani E. Gor M. C. Scott P. C. Moore R. J. (2016). Campylobacter hepaticus sp. nov., isolated from chickens with spotty liver disease. Int. J. Syst. Evol. Microbiol.66, 45184524. 10.1099/ijsem.0.001383

  • 223

    Vandenberg O. Houf K. Douat N. Vlaes L. Retore P. Butzler J.-P. et al . (2006). Antimicrobial susceptibility of clinical isolates of non-jejuni/coli campylobacters and arcobacters from Belgium. J. Antimicrob. Chemother.57, 908913. 10.1093/jac/dkl080

  • 224

    Viejo G. Gomez B. De Miguel D. Del Valle A. Otero L. De La Iglesia P. (2001). Campylobacter fetus subspecies fetus bacteremia associated with chorioamnionitis and intact fetal membranes. Scand. J. Infect. Dis.33, 126127. 10.1080/003655401750065517

  • 225

    Von Troil-Lindén B. Torkko H. Alaluusua S. Jousimies-Somer H. Asikainen S. (1995). Salivary levels of suspected periodontal pathogens in relation to periodontal status and treatment. J. Dent. Res.74, 17891795. 10.1177/00220345950740111201

  • 226

    Walsh A. Mabee J. Trivedi K. (2011). Inflammatory bowel disease. Prim. Care38, 415432. 10.1016/j.pop.2011.06.001

  • 227

    Wang B. Kraig E. Kolodrubetz D. (2000). Use of defined mutants to assess the role of the Campylobacter rectus S-layer in bacterium-epithelial cell interactions. Infect. Immun.68, 14651473. 10.1128/IAI.68.3.1465-1473.2000

  • 228

    Wang Y. Liu F. Zhang X. Chung H. K. Riordan S. M. Grimm M. C. et al . (2017). Campylobacter concisus genomospecies 2 is better adapted to the human gastrointestinal tract as compared with Campylobacter concisus genomospecies 1. Front. Physiol.8:543. 10.3389/fphys.2017.00543

  • 229

    Wassenaar T. M. Bleumink-Pluym N. Van Der Zeijst B. (1991). Inactivation of Campylobacter jejuni flagellin genes by homologous recombination demonstrates that flaA but not flaB is required for invasion. EMBO J.10:2055.

  • 230

    Wassenaar T. M. Van Der Zeijst B. A. Ayling R. Newell D. G. (1993). Colonization of chicks by motility mutants of Campylobacter jejuni demonstrates the importance of flagellin A expression. Microbiology139, 11711175. 10.1099/00221287-139-6-1171

  • 231

    Watson R. O. Galán J. E. (2005). Signal transduction in Campylobacter jejuni-induced cytokine production. Cell. Microbiol.7, 655665. 10.1111/j.1462-5822.2004.00498.x

  • 232

    Weisblum B. (1995). Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother.39:577. 10.1128/AAC.39.3.577

  • 233

    Werno A. M. Klena J. D. Shaw G. M. Murdoch D. R. (2002). Fatal case of Campylobacter lari prosthetic joint infection and bacteremia in an immunocompetent patient. J. Clin. Microbiol.40, 10531055. 10.1128/JCM.40.3.1053-1055.2002

  • 234

    Williams C. S. Mann M. Dubois R. N. (1999). The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18. 10.1038/sj.onc.1203286

  • 235

    Wolfs T. F. Duim B. Geelen S. P. Rigter A. Thomson-Carter F. Fleer A. et al . (2001). Neonatal sepsis by Campylobacter jejuni: genetically proven transmission from a household puppy. Clin. Infect. Dis.32, e97e99. 10.1086/319224

  • 236

    Wyatt J. Vogelsang H. Hubl W. Waldhoer T. Lochs H. (1993). Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet341, 14371439. 10.1016/0140-6736(93)90882-H

  • 237

    Xiao T. S. (2015). The nucleic acid-sensing inflammasomes. Immunol. Rev.265, 103111. 10.1111/imr.12281

  • 238

    Yang L. Lu X. Nossa C. W. Francois F. Peek R. M. Pei Z. (2009). Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology137, 588597. 10.1053/j.gastro.2009.04.046

  • 239

    Yeo A. Smith M. A. Lin D. Riché E. L. Moore A. Elter J. et al . (2005). Campylobacter rectus mediates growth restriction in pregnant mice. J. Periodontol.76, 551557. 10.1902/jop.2005.76.4.551

  • 240

    Young K. T. Davis L. M. Dirita V. J. (2007). Campylobacter jejuni: molecular biology and pathogenesis. Nat. Rev. Microbiol.5, 665679. 10.1038/nrmicro1718

  • 241

    Yu W.-L. Chen W.-Y. (1997). Tubo-ovarian abscess caused by multidrug resistant Bacteroides gracilis. J. Formos. Med. Assoc.96, 457460.

  • 242

    Zhang L. (2015). Oral Campylobacter species: Initiators of a subgroup of inflammatory bowel disease?World J. Gastroenterol.21, 92399244. 10.3748/wjg.v21.i31.9239

  • 243

    Zhang L. Budiman V. Day A. S. Mitchell H. Lemberg D. A. Riordan S. M. et al . (2010). Isolation and detection of Campylobacter concisus from saliva of healthy individuals and patients with inflammatory bowel disease. J. Clin. Microbiol.48, 29652967. 10.1128/JCM.02391-09

  • 244

    Zhang L. Lee H. Grimm M. C. Riordan S. M. Day A. S. Lemberg D. A. (2014). Campylobacter concisus and inflammatory bowel disease. World J. Gastroenterol.20, 12591267. 10.3748/wjg.v20.i5.1259

  • 245

    Zhang L. Man S. M. Day A. S. Leach S. T. Lemberg D. A. Dutt S. et al . (2009). Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn's disease. J. Clin. Microbiol.47, 453455. 10.1128/JCM.01949-08

Summary

Keywords

Campylobacter concisus , inflammatory bowel disease, human hosted Campylobacter, virulence factor, bacterial marker, transmission, oral Campylobacter, pathogenic mechanism

Citation

Liu F, Ma R, Wang Y and Zhang L (2018) The Clinical Importance of Campylobacter concisus and Other Human Hosted Campylobacter Species. Front. Cell. Infect. Microbiol. 8:243. doi: 10.3389/fcimb.2018.00243

Received

13 March 2018

Accepted

25 June 2018

Published

24 July 2018

Volume

8 - 2018

Edited by

Wilhelmina May Huston, University of Technology Sydney, Australia

Reviewed by

Deborah Threadgill, Texas A&M University, United States; Zuowei Wu, Iowa State University, United States

Updates

Copyright

*Correspondence: Li Zhang

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics